November 16-19, 2017 Marriott Marquis San Francisco ... SNO_Program_fin… · Marriott Marquis San Francisco, California. ... Kohichi Ichimura Kurt Jaeckle Rakesh Jalali ... Paul

M E E T I N G P R O G R A M

22 N D A N N UA L M E E T I N Gand E D U C AT I O N D AY

O F T H E S O C I E T Y F O R N E U R O - O N C O L O G Y

November 16-19, 2017Marriott Marquis

San Francisco, California

2 I 22ND Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology



16916305PCOD_OPT-0048_SNO_Ad_M3

Important Safety InformationContraindications

©2017 Novocure. All rights reserved. Optune and Novocure are trademarks of Novocure. OPT-1299

Indication For Use Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Proven superior long-term survival with Optune® + TMZ vs TMZ alone with 5 years of clinical evidence1,2,*

5-year survival analyses1

Optune + TMZ also significantly improved PFS vs TMZ alone¹ • Median: 6.7 months vs 4.0 months (P=0.00005)

Optune + TMZ has demonstrated consistent superiority vs TMZ alone in all analyses since the interim results were reported² • Median OS: 20.5 months vs 15.6 months (P=0.0042) • Median PFS: 7.2 months vs 4.0 months (P=0.0013)

*Both interim and 5-year survival analyses are protocol prespecified.3

GBM, glioblastoma; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide.

Unprecedented 5-year survival results in newly diagnosed GBM1

i am proofof long-term survival in newly diagnosed GBM1

Median OS (P=0.00006)

Optune + TMZ

MONTHS MONTHS

TMZ alone

16.020.9 vs

5-year OS (P=0.004)

Optune + TMZ TMZ alone

5%13% vs

Proven to provide the best chance for2.5x greater overall survival at 5 years vs TMZ alone

Marcia is an Optune patient.

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.Warnings and PrecautionsOptune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure™ (the device manufacturer).Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea,

constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

References: 1. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 2. Optune Instructions For Use. Novocure 2016. 3. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535-2543.

Please visit Optune.com/IFU for Optune Instructions For Use (IFU) for complete information regarding the device’s indication, contraindications, warnings, and precautions.

TA B L E O F C O N T E N T S

SNO Committees, Reviewers and Exhibitors 4Meeting Overview 6Ancillary Meetings 8Meeting Room and Exhibitor Maps 9Poster Maps 12Meeting Program 14- Thursday 16 - Friday 18 - Saturday 29 - Sunday 39

22ND Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology I 3




Platinum Supporters

The Society for Neuro-Oncology gratefully acknowledges the SNO Platinum Partners listed below. Their on-going support allows SNO to fulfill its mission to advance neuro-oncology research and education. AbbVie American Brain Tumor Association AstraZeneca The Brain Tumour Charity Bristol-Myers Squibb Genentech National Brain Tumor Society Novocure The Sontag Foundation

Educational Supporter The conference organizing committee wishes to express appreciation to the following company for its commitment to continuing medical education by providing an educational grant in support of this conference:

Celgene

Scientific Committee

Scientific Meeting Chairs Manish Aghi Frank Furnari Vinay Puduvalli

Education Day Chairs Susan Bell Robert Cavaliere Albert Kim Khalid Shah

Meeting Technology Erik Sulman

Awards Committee Tracy Batchelor (Chair) Manish Aghi Christina Amidei Frank Furnari Daphne Haas-Kogan Vinay Puduvalli

Poster Awards Committee Prakash Chinnaiyan Jennifer Clarke Biplab Dasgupta Morris Groves Priya Kumthekar Aaron Mammoser Theodore Nicolaides Josh Neman-Ebrahim Marta Penas-Prado Joanna Phillips David Raleigh Reena Thomas

Meeting Supporters

The Society for Neuro-Oncology wishes to express appreciation to the organizations listed below for their promotional support of this meeting.

Benefactor Level Brainlab CERN Foundation Orbus Therapeutics

Contributor Level Cancer Research UK Celgene Elekta Nativis Inc. Northwest Biotherapeutics The EndBrainCancer Initiative Tocagen

Meeting Exhibitors

AbbVie Ambry Genetics American Brain Tumor Association Arbor Pharmaceuticals, LLC AstraZeneca The Brain Tumour Charity Brainlab BriovaRX Bristol-Myers Squibb Caris Life Sciences CERN Foundation City of Hope Laboratories Elekta EndBrainCancer Initiative Genentech Houston Methodist Hospital - Peak Center Imaging Biometrics LLC Inovio Pharmaceuticals Integrated Oncology, LabCorpIsoray Medical Li-Fraumeni Syndrome AssociationMagForce AG Make-A-Wish Foundation Med Learning Group Monteris Medical National Brain Tumor Society Nativis Inc. NICO CorporationNorthwest Biotherapeutics Novartis OncologyNovocure Orbus Therapeutics Inc. Oxford University Press PathGroup SmartGenomicsTM

Renishaw PLC Synaptive Medical The International Brain Tumour Alliance (IBTA) The Sontag Foundation & Brain Tumor NetworkTocagen, Inc. UC Irvine Health UCB, Inc. University of Florida Neuroscience

2017 SNO Officers

President E. Antonio Chiocca, MD, PhD

Vice President Terri Armstrong, APN, PhD

Secretary-Treasurer Gelareh Zadeh, MD, PhD

Board of Directors Christina Amidei, MSN, PhD Tracy Batchelor, MD Priscilla Brastianos, MD Daniel Brat, MD, PhD Frank Furnari, PhD Daphne Haas-Kogan, MD Ingo Mellinghoff, MD Whitney Pope, MD, PhD John Sampson, MD, PhD Erik Sulman, MD, PhD Jeffrey Wefel, PhD

Past President David Reardon, MD

Foundation Board Victor A. Levin, MD (SNO Founder) Mitchel S. Berger, MD Susan Chang, MD

Neuro-Oncology Patrick Wen, MD (Editor-in-Chief) Kenneth Aldape, MD (SNO Editor)

Neuro-Oncology Practice Susan Chang (Editor-in-Chief) Jeffrey Wefel (SNO Editor)

WFNOS Magazine Nicholas Butowski (SNO Editor)

SNO Staff

Executive Director J. Charles Haynes, JD

Manager of Medical Education Carolyn Loch

Manager, Member & Program Services Linda Greer

Marketing & Exhibits Coordinator Megan Bell-Johnston

Meetings & Events Specialist Ginger Vazquez

Communications Coordinator Kristin Odom

Bookkeeper Martha Maloch

Abstract Reviewers


Manish AghiManmeet AhluwaliaKen AldapeNduka AmankulorTerri ArmstrongIsabel ArrillagaBehnam BadieRamon BarajasFred BarkerJill Barnholtz-SloanTracy Batchelor Oren BecherMichael BerensKrishna BhatJaeshri BlakeleyOrin BlochAdrienne BoireMelissa BondyEric BouffetPriscilla BrastianosDaniel BratSteve BraunsteinSevera BundaNicholas ButowskiDaniel CahillJian CampianSusan ChangClark ChenShiyuan ChengOlivier ChinotJennifer ClarkeElizabeth ClausRivka ColenHoward ColmanHeather ConklinDenise CorreaJoseph CostelloWilliam CurryJohn de GrootLisa DeAngelisAaron DiazJorg DietrichJan DrappatzGavin DunnDavid EisenstatBenjamin EllingsonPeter FecciOlavo FeherHoward FineJonathan FinlayJohn FiveashEkokobe FonkemDeborah ForstMaryam Fouladi

Frank FurnariAmar GajjarEva GalanisNorbert GalldiksIsabelle GermanoElizabeth GerstnerPierre GiglioMark GilbertJakub GodlewskiWolfgang GrisoldChristian GrommesMorris D GrovesDeliang GuoDavid GutmannConstantinos HadjipanayisSamir HannaMonika HegiAmy HeimbergerJohn HensonShawn Hervey-JumperChristopher HessYuichi HiroseAnnie HuangMatthew HuntKohichi IchimuraKurt JaeckleRakesh JalaliC. David JamesRandy JensenDavid JonesTimothy KaufmannBalveen KaurSantosh KesariSoumen KhatuaPhilipp KickingerederMark KieranChifumi KitanakaMartin KleinTakashi KomoriPaul KongkhamJohn KuoMadan KwatraAlbert LaiKatrin LamszusJustin LathiaGordon LiKeith LigonMichael LimMary P. LovelyZhimin LuJanine LupoAnita MahajanElizabeth MaherMarcos Maldaun

Daniel MarquesSuely Maymone-MeloKerrie McDonaldMinesh MehtaIngo MellinghoffThomas MerchantC. Ryan MillerDuane MitchellSandy MitchellShin-Ichi MiyatakeAnnette MolinaroMichelle Monje-DeisserothSabine MuellerAkitake MukasaMotoo NaganeSeema NagpalBrian NahedJean NakamuraIchiro NakanoAtsushi NatsumeLakshmi NayakSarah NelsonSimone NiclouTheo NicolaidesRyo NishikawaPaul A. NorthcottBrian Patrick O’NeillNancy Ann Oberheim-BushHideho OkadaAntonio OmuroPatrick PaddisonMargaretta PageChul-kee ParkDeric M. ParkMichael ParsonsMarta Penas-PradoJames PerryArie PerryClaudia PetritschHeidi PhillipsJoanna J. PhillipsRussell PieperMarshall PitzScott PlotkinScott PomeroyWhitney PopeVinay K. PuduvalliEudocia Quant-LeeRuman RahmanRohan RamakrishnaGanesh RaoOtto RapalinoRaju RavalDavid Reardon

Brent ReynoldsJeremy RichDavid RobergeLisa RogersSabrina RonenAlasdair RooneyMark RosenthalSussan SalasJann SarkariaDavid SchiffSoma SenguptaWenyin ShiStephanie Shook-PughSheila SinghTania SlatterYukihiko SonodaPatricia SteegCharles StilesRoger StuppErik SulmanMario SuvaGhazaleh TabatabaiMartin TaphoornMichael TaylorJennie TaylorKeita TerashimaJoerg-Christian TonnKeisuke UekiJoon UhmMartin van den BentErwin Van MeirMonica VenereRoel VerhaakMichael VogelbaumDerek WainwrightTobias WalbertKyle WalshZhaohui WangColin WattsJeffrey WefelWilliam WeissMary WelchMichael WellerPatrick Y. WenLeonardo WendlingCynthia WetmoreWolfgang WickMargaret WrenschJing WuStephen YipRobert J. YoungJohn YuGelareh ZadehJay-Jiguang Zhu

Mia BertalanNathaniel BoydKelly BraunRodica Di LorenzoMelissa EdwardsJenny Firkins

Grace FurnariAlex KaplanFred LamCatherine LibbyAlan Thinh NguyenJescelica Ortiz Rivera

Aimee SatoFernando Santos-PinheiroAshlee SeldomridgePratibha SharmaGaurav ShuklaMatthew Smith-Cohn

Jessica SwannerAnh TranSebastian WinterJasmine WuDiana Yu

Monitors

MEETING OVERVIEW

The 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology will take place at the Marriott Marquis Hotel in San Francisco, California. With a prime location in central San Francisco, only blocks away are museums, shops, restaurants, cable cars, Chinatown, Union Square and many other popular attractions. The Marriott Marquis offers panoramic views of the city from its 39th floor sky high bar and is only 13 miles from the San Francisco International Airport and 19 miles from Oakland International airport. In addition to a lively downtown, there are many sites to explore with unique neighborhoods in hilly terrain, waterfront districts, trendy bistros and beautiful views of the Golden Gate Bridge.

This year’s Education Day will focus on two of the Cancer Moonshot Blue Ribbon Panel recommendations, “Developing Ways to Overcome Cancer Resistance,” and “Minimizing Cancer Treatments Debilitating Side Effects.” In addition to concurrent sessions with both Basic Science and Applied Neuro-Oncology presenting a comprehensive view of these topics, there will also be morning and afternoon joint sessions with exciting talks from prominent keynote speakers and lively discussion panels.

CANCER MOONSHOT SESSIONS

This year’s Scientific Meeting will highlight a number of the 10 Blue Ribbon Panel recommendations related to the Cancer Moonshot program. Dr. W. K. Alfred Yung, a member of the Blue Ribbon Panel, will present an introduction to the Moonshot program. Additional keynote presentations from Dr. Jennifer Doudna, Dr. Walter Koroshetz, Dr. Ludmil Alexandrov and Dr. Carlo Croce will provide further insights into specific approaches in meeting the goals of these Cancer Moonshot recommendations. These, and additional key talks and sessions related to the Moonshot initiative, are identified by the Moonshot logo:

NEW THIS YEAR! The SNO meeting will provide some exciting new

features this year including:

• CLAIM CME CREDIT DIRECTLY THROUGH THE APP

• ENHANCED “TEXT TO MODERATOR” ELECTRONIC Q&A

• SELECTED SESSIONS SIMULCASTED ON HOTEL IN-ROOM TV AT THE MARRIOT

• EXPANDED E-TALKS WITH 45 FLAT SCREENS PLACED THROUGHOUT THE MEETING SPACE

• NEW PRESENTATION MANAGEMENT SYSTEM FOR EASIER UPLOAD OF ORAL PRESENTATIONS

• CAPTURE OF SELECTED CONTENT FOR POST-MEETING EDUCATION SITE

Building on the success of past SNO meetings, sunrise sessions, plenary and concurrent sessions will be featured with oral abstract presentations, enhanced oral eTalk electronic poster presentations, and poster presentations. Special lunch tutorials and industry-sponsored symposia will provide in-depth information on evolving technologies and therapeutics. Circulated for viewing throughout the meeting will be webcasts with “Meet the Expert” recordings of esteemed scientists and clinicians on topics such as mouse models, The Cancer Genome Atlas, telomeres, genetics and epigenetics of pediatric brain tumors, and immunology checkpoint inhibitors. The SNO Daily Highlights will again be recorded for viewing, with invited discussants reviewing the most cutting-edge science from that day’s basic science and clinical research presentations. Interactive ePoster touch screens will be available throughout the meeting venue.

SNO Daily Highlights will again be featured this year, in which invited discussants will review the most cutting-edge science from that day’s basic science and clinical research presentations. The SNO Daily Highlights will be video-taped and made available for viewing that same evening via the meeting app and periodically on channels 59 and 60 in the Marriott Marquis hotel rooms.

Friday Discussants Erwin Van Meir Jing Wu

Saturday Discussants Monica Venere Isabel Germano

Sunday Recap Manish Aghi Frank Furnari Vinay Puduvalli

SNO DAILY HIGHLIGHTS

Be sure to watch SNO’s Meet the Expert Videos, which will be available for viewing throughout the conference area and periodically on channels 59 and 60 in the Marriott Marquis hotel rooms. These 10-minute, videotaped talks by esteemed scientists and clinicians provide an overview of some of the key issues in brain tumor research. This year’s topics include brain metastases, viral gene therapy, immunology, checkpoint Inhibitors, and genetics and epigenetics of pediatric brain tumors.

PresentersIrving WeissmanImmunology and checkpoint inhibitors

Stefan PfisterDeciphering genetics and epigenetics of pediatric brain cancers

Maria Castro, Pedro LowensteinViral mediated immunotherapy for brain cancer: reprogramming the brain immune system

Manmeet AhluwaliaBrain metastases

e-TALKS

Don’t miss this year’s e-Talk sessions on Friday and Saturday evenings. Located in Golden Gate C1-C-3, these interactive 4-minute oral e-Talk presentations are followed by discussion in the main poster area at designated flat screens.

Friday (See pages 26-28 for full speaker list)

Group 1: 7:30-8:30pm – Cell Signaling, Genetics, Epigenetics Group 2: 7:30-8:30pm – Drug Resistance, Experimental Therapeutics, Metabolism Group 3: 7:30-8:30pm – Imaging, Pediatrics, Outcomes, Practical & Applied Neuro-Oncology, Pathology

Saturday (See pages 36-38 for full speaker list)

Group 1: 5:00-6:00pm – Adult Therapeutics Group 2: 5:00-6:00pm – Angiogenesis, Invasion, Microenvironment, Immunology Group 3: 5:00-6:00pm – Pediatric Basic Science, Stem Cells

MEET THE EXPERTS VIDEOS

TV SIMULCAST

This year, select sessions of the main meeting will be simulcast to the Marriott Marquis hotel rooms via channels 59 and 60. These sessions are identified in the program by this icon:


EDUCATIONAL OBJECTIVES

After attending this conference, participants should be able to:

• Discuss new CNS cancer technologies in the areas of cell biology, cell signaling, genetics, epigenetics, immunology, stem cells, metabolomics, tumor microenvironment, angiogenesis and radiobiology (knowledge);

• Identify ways to overcome cancer resistance (knowledge);• Apply information on minimizing side effects from cancer treatment

(knowledge, competence, performance, patient outcomes);• Describe new advances in the treatment of CNS metastases

(knowledge);• Apply advances in neuro-imaging and neuropathology to diagnose,

prognose, and measure response to therapy for patients with CNS tumors (knowledge, competence, performance, patient outcomes);

• Apply therapeutic strategies and clinical trial designs related to new molecular biology research relevant to CNS tumors (competence);

• Using neurocognitive intervention strategies, create a plan to diminish the impact of brain tumors and their treatments on patients and quality of life (knowledge, competence, performance, patient outcomes)

TARGET AUDIENCE This conference should be of value to neuro-oncologists, medical oncologists,adult and pediatric neurosurgeons, pediatric neuro-oncologists, neuroradiologists, neuropathologists, radiation oncologists, neuro-psychologists, epidemiologists, basic and translational scientists and nurses.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding AMA PRA Category 1 Credit™ will only be available online via the SNO app and/or website. These will be available from the start of the meeting through 4 weeks following the end of the meeting. Physicians will be directed to the evaluation questionnaire and a CME Verification Form which must be completed prior to the CME certificate being displayed. Once displayed the certificate may be printed or downloaded. An email address may also be entered to send the certificate. A record of the CME certificate will be saved for future access.

Certificates of attendance will also be available online via the app and/or website for other health care professionals and international faculty upon completion of the evaluation form. This certificate may be used in verifying attendance or for requesting credits with state nursing boards, specialty societies or other professional associations. A record of this certificate will be saved for future access.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially influence the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.


SPEAKER READY ROOM

All oral presenters will need to drop off their slides in the Speaker Ready Room located in Willow if they did not previously upload them via the web. Check your email for presentation requirements.

INTERNET ACCESS

Wifi is available in the main conference rooms and foyer areas. Network name: SNOMeeting Password: SNO2017Charging stations for mobile devices can be found in the foyer areas of the two main ballrooms.

SNO CAREER LOUNGE

The “SNO Career Lounge” facilitates a convenient environment where prospective candidates and employers can connect. The Career Lounge is located in the Laurel room of the Marriott Marquis Hotel, and will be open Thursday, Friday and Saturday, from 10:00am to 4:00pm.

SNO APP

Download the official SNO 22nd Annual Meeting mobile app for the 2017 Scientific Meeting and Education Day! The SNO 22nd Annual Meeting app serves as your all-in-one event guide by putting everything you need to know right onto your mobile device. Customize your conference experience by creating your schedule in advance, communicate with other attendees during the event, follow along with presentations, and take session notes. Access the Attendee Directory to connect with new acquaintances, browse the scientific abstracts, submit questions for presenters during sessions, claim CME and view daily video previews/highlights of the day.

SNO 22nd Annual Meeting app is currently available for free in the App Store and Android Market, just search for “SNO2017,” or visit the registration area for technological assistance. You must sign in to have access to the mobile app. Please

create an account using your email address and a password. It must be the same email address used when registering for the meeting. If you use an alternate email address you will not have access to content on this site. Create your own password for the mobile app.

EDUCATIONAL METHODS

Lectures, Question-and-Answer Sessions, Panel Discussions, Posters, etc. EVALUATION

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 27.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The presentations included in the Applied Neuro-Oncology (Quality of Life) Interventions section have been designated by The University of Texas MD Anderson Cancer Center for 2.5 AMA PRA Category 1 CreditsTM in medical ethics and/or professional responsibility.

A N C I L L A R Y & C O M M I T T E E M E E T I N G S


Thursday, November 16, 2017

Time Function Room 12:00-1:00pm SNO Guidelines Committee Meeting Foothill F 12:00-2:00pm Tocagen Investigator Meeting Foothill H 12:00-2:00pm Ivy Consortium Investigator Meeting Foothill D 1:00-5:00pm GLASS F2F Meeting #3 Foothill B 2:30-5:00pm NCI Brain Malignancies Steering Committee Meeting Foothill E 4:00-5:00pm CBTC Investigator Meeting Foothill H5:30-7:30pm GBM Heroes Gala 2017 – Guest Speaker: Maria Menounos City View at the Metreon See map, page 115:30-7:30pm SNO Board of Directors Meeting Foothill F 7:30-9:30pm Agios Reception Foothill A

Friday, November 17, 2017

Time Function Room 6:30-8:00am Monteris Medical FLAG Meeting Foothill F 6:30-8:30am Neuro-Oncology Editorial Meeting Nob Hill AB 7:00-8:00am H. Lee Moffitt Cancer Center gliomaSE Consortium Meeting Foothill J 7:00-8:30am Tocagen Non-Profit Organization Breakfast Pacific I 12:15-1:15pm Carol Kruchko Celebration Foothill A 12:15-1:15pm IRANO Working Group Foothill E 12:15-1:15pm Roche Investigator Update Pre Meeting Pacific D 4:00-5:00pm SNO Public Policy Pacific D 5:00-6:00pm Neuro-Oncology Fellowship Program Directors Meeting Foothill F 5:30-7:00pm EANO Palliative Care Task Force Meeting Foothill J 5:30-7:00pm MSKCC Neurology Faculty Reunion The View Lounge 5:30-7:30pm CERN Foundation Reception Foothill G 5:30-7:30pm Collaborative Opportunities with the Blood-Brain Barrier Foothill C Consortium for Diagnostic and Therapeutic Clinical Trials 5:30-7:30pm Inovio GBM-001 Investigator Update Sierra E 5:30-7:30pm International Neoplastic Meningitis Consortium Meeting Foothill D 5:30-7:30pm MGH/DFCI/BWH Neuro-Oncology Fellowship Reception Foothill A 5:30-7:30pm Tocagen Reception Foothill B 5:30-7:30pm UCSF Reception SoMa 8:00-9:00pm World Federation of Neuro-Oncology Societies (WFNOS) General Assembly Foothill F 9:30-11:00pm SNO Invited Faculty Reception View Lounge - Twin Peaks

Time Function Room

6:30-8:30am Neuro-Oncology Practice Editorial Meeting Nob Hill AB 6:30-8:30am Roche Investigator Update Meeting Foothill E 6:30-8:30am Tocagen Advisory Board Meeting Pacific I 7:00-8:00am NANO Working Group Meeting Foothill J 12:15-1:15pm METIS Meeting Pacific I 5:30-7:00pm Brain Tumor Funders Committee - Long Term Survival in GBM Foothill B

Time Function Room

6:30-8:30am VBL Meeting Foothill B 7:30-8:30am SNO Partners Advisory Breakfast Nob Hill CD

Sunday, November 19, 2017

Saturday, November 18, 2017


M E E T I N G R O O M S ; E X H I B I T M A P

Society for Neuro-OncologySNO

4545 West Davis St.Dallas, TX 75211

214.623.1300

Marriott Marquis SF

Golden Gate

VENUE

EVENT

PRODUCTION

DRAWING DETAILS

ROOM SET UP DETAIL

VERSION:

REVISION DATE:

DRAWN BY:

SCALE:

1

09/12/2017

Jason Bailey

As Noted

ROOM:

FUNCTION:

DATE:

SEATING STYLE:

SEATING COUNT:

E Poster SessionsE Talks

Nov 15-19, 2017

NA

As Noted

F R E E M A NAudio Visual Solutions, Inc.

San Francisco, CA

ALL FLOORPLANS ARE SUBJECT TO FINALAPPROVAL BY LOCAL FIRE MARSHAL

2017

Any notes can go here

DRAWING NOTES

This document contains confidential and proprietary information that

may not be reproduced or divulged, in whole or in part, without written

authorization from Freeman Audio Visual, Inc.

Every effort has been made to ensure the accuracy of the floorplan.

No warranties, either expressed or implied are made.

Copyright © FREEMAN All rights reserved.

205 206

207

208

213T 212T 211T 210T 209T

202

201

203T 204T

ePoster

ePoster

E Poster SessionC3

E Poster SessionC2

E Poster SessionC1

5amp 120v drop at each monitor standTotal 23 Drops

54" h x 8' w

6'-7"

Lens to Screen (straight): 12'-9.6"

SxA 250

SxA 250

8'

6' 18"

8'

6'

54" h x 8' w6'-7"


SxA 250

SxA 250

8'

6'18"

8'

6'

54" h x 8' w

6'-7"


SxA 250

SxA 250

8'

6'18"

8'

6'

16

24

40 40 40 40 40

2424 24 24 24

18

18

Escalators to LobbyTo Yerba Buena

Golden Gate Ballroom B2 Floor

e-Posters

e-Talk PresentationsC3



Organization Name LocationAbbVie 115/116AbbVie 201/202Ambry Genetics 211American Brain Tumor Association 112Arbor Pharmaceuticals, LLC 123AstraZeneca 214The Brain Tumour Charity 106Brainlab 305BriovaRX 203Bristol-Myers Squibb 107Caris Life Sciences 208

Organization Name Location CERN Foundation 302City of Hope Laboratories 212Elekta 111EndBrainCancer Initiative 122Genentech 109Houston Methodist Hospital - Peak Center 205Imaging Biometrics LLC 301Inovio Pharmaceuticals 207Integrated Oncology, LabCorp 110Isoray Medical 307Li-Fraumeni Syndrome Association 310MagForce AG 204Make-A-Wish Foundation 113Med Learning Group 209Monteris Medical 309National Brain Tumor Society 114Nativis Inc. 121NICO Corporation 303Northwest Biotherapeutics 210Novartis Oncology 108Novocure 117/118/119Orbus Therapeutics Inc. 104Oxford University Press 101PathGroup SmartGenomics™ 213Renishaw PLC 124Synaptive Medical 206The International Brain Tumour Alliance(IBTA) 304The Sontag Foundation & Brain Tumor Network 105Tocagen, Inc. 102UC Irvine Health 306UCB, Inc. 308University of Florida Neuroscience 103

EXHIBITORS


M E E T I N G R O O M S ; E X H I B I T M A P

SALONS 10-12

SALONS 13-15

SALONS 4-6

SALONS 1-3

NOB HILLAB

NOB HILLCD

To Golden Gate

To Golden GateTo Yerba Buena

SALON 7

SALON 8

SALON 9

Registration

Yerba Buena Ballrooms Lower B2 Floor

Golden Gate Ballroom B2 Floor

Foothill Meeting Rooms 2nd Floor Pacific Meeting Rooms 4th Floor Sierra Meeting Room 5th Floor

General Assembly

W E L C O M E R E C E P T I O N M A P


Directions:- Exit to the rear of the Marriott Marquis San Francisco hotel towards Yerba Buena Ln.- Make a right on Yerba Buena Ln.- Cross Mission St.- Enter the Metreon building to your right.- Take the escalators up to the 4th Floor.

Metreon Building

Marriott Marquis

Mission St

.

Yerba Buena Ln.

Yerba Buena Gardens

City View at Metreon

4th St.

4th St.

Thursday, November 16 City View at Metreon

ACTR Adult Clinical Trials - Non-ImmunologicANGI Angiogenesis and InvasionATIM Adult Clinical Trials - ImmunologicCBIO Cell BiologyCMET CNS MetastasisCSIG Cell Signaling and Signaling PathwaysDDIS Drug DiscoveryDRES Drug ResistanceEPID EpidemiologyEXTH Experimental Therapeutics - Non-ImmunologicalGENE Genetics and Epigenetics

HOUT Health Outcome MeasuresIMMU ImmunologyMETB MetabolomicsMNGI MeningiomaNCMP Neurological Complications of CancerNCOG Neuro-Cognitive OutcomesNIMG NeuroimagingNTOX Neurotoxicity of Cancer TreatmentPALL Supportive Palliative CarePATH Molecular Pathology and Classification - Adult and PediatricPDCT Pediatric Clinical Trials and Outcomes

PDTM Pediatric Tumors - Non-ImmunologicalQLIF Quality of LifeRARE Rare TumorsRBIO RadiobiologyRTHP Radiation TherapySTEM Stem CellsSURG Surgical TherapyTMIC Tumor MicroenvironmentTMOD Tumor Models

A B S T R A C T C O D E S

P O S T E R S Friday, November 17, 2017


QLIF

PATH

PATHPALL

QLIF QLIFQLIFNCOG

NIMGNCMP

NIMG

NIMG NIMG

HOUTHOUT

HOUT

NIMG

GENE GENE

GENEGENEEXTH

EXTHEXTH

EXTHEXTH

CSIG

TMICCBIOACTR

DRES

PDCT

PDCT

CBIO

PATH

HOUT HOUT

EXTH

DRES

CSIG

ACTR - Adult Clinical Trials – Non-Immunologic

CBIO - Cell Biology

CSIG - Cell Signaling and Signaling Pathways

DRES – Drug Resistance

EXTH – Experimental Therapeutics – Non Immunological

GENE- Genetics and Epigenetics

HOUT – Health Outcome Measures

NCMP – Neurological Complications

NTO

X

NCOG – Neuro-Cognitive Outcomes

NIMG - Neuroimaging

NTOX – Neurotoxicity of Cancer Treatment

PALL – Supportive Palliative Care

PATH – Molecular Pathology and Classification – Adult and Pediatric

PDCT – Pediatric Clinical Trials and OutcomesQLIF – Quality of LifeTMIC – Tumor Microenvironment

ACTR - Adult Clinical Trials - Non-ImmunologicCBIO - Cell BiologyCSIG - Cell Signaling and Signaling PathwaysDRES - Drug ResistanceEXTH - Experimental Therapeutics - Non-ImmunologicalGENE - Genetics and EpigeneticsHOUT - Health Outcome MeasuresMETB - MetabolomicsNCMP - Neurological Complications

NCOG - Neuro-Cognitive OutcomesNIMG - NeuroimagingNTOX - Neurotoxicity of Cancer TreatmentPALL - Supportive Palliative CarePATH - Molecular Pathology and Classification – Adult and PediatricPDCT - Pediatric Clinical Trials and OutcomesQLIF - Quality of LifeTMIC - Tumor Microenvironment

Entrance

Entrance

e-Posters

Golden Gate Ballroom




B2 Floor

TMOD TMOD

TMIC TMIC

STEMSTEMSURGSURG

RTHPRTHP

RBIORARERARE

PDTMMNGI

IMMU

EPID

IMMU

EPIDIMMU

PDTM

ANGIANGI

DDISCMETCMET

ATIMATIMATIM/CBIO

ACTRACTRACTR

TMO

D

TMIC

DDIS

TMOD

STEM

SURG

DDIS

RTHP

ACTR

MNGI

DDIS

CMETCMETANGI

ACTR ACTR

ACTR

ACTR – Adult Clinical Trials – Non-ImmunologicANGI – Angiogenesis and InvasionATIM – Adult Clinical Trials - ImmunologicCBIO – Cell BiologyCMET – CNS MetastasisDDIS – Drug DiscoveryEPID - EpidemiologyIMMU - ImmunologyMNGI - MeningiomaPDTM – Pediatric Tumors-non-immunologicalRARE – Rare TumorsRBIO - RadiobiologyRTHP – Radiation TherapySTEM – Stem CellsSURG – Surgical TherapyTMIC – Tumor MicroenvironmentTMOD – Tumor Models

P O S T E R S Saturday, November 18, 2017


ACTR - Adult Clinical Trials - Non-ImmunologicANGI - Angiogenesis and InvasionATIM - Adult Clinical Trials - ImmunologicCBIO - Cell BiologyCMET - CNS MetastasisDDIS - Drug DiscoveryEPID - EpidemiologyIMMU - ImmunologyMNGI - Meningioma

PDTM - Pediatric Tumors-non-immunologicalRARE - Rare TumorsRBIO - RadiobiologyRTHP - Radiation TherapySTEM - Stem CellsSURG - Surgical TherapyTMIC - Tumor MicroenvironmentTMOD - Tumor Models

Entrance

Entrance

e-Posters

Golden Gate Ballroom




B2 Floor


Yerba Buena Salon 9

Yerba Buena Salon 8

P R O G R A M AT A G L A N C EThursday, November 16, 2017 Education Day

8:00 - 9:10am MORNING JOINT SESSION8:00 - 8:10am Welcome and Introduction8:10 - 8:40am Keynote Presentation: Trever Bivona8:40 - 9:10am Keynote Presentation: Donald I Abrams

9:10 - 9:30am Break

10:00 - 12:00pm BREAKOUT: Practical and Applied Neuro-Oncology Survivorship and Measuing Outcomes

9:30 - 11:35am BREAKOUT: Tumor Biology and Therapy Biology of Resistance

11:35 - 12:35pm Lunch

12:35 - 2:40pm BREAKOUT: Practical and Applied Neuro-Oncology Mitigating Effects of Treatment and Disease

12:35 - 2:40pm BREAKOUT: Tumor Biology and Therapy Therapy-specific Resistance Mechanisms

2:40 - 3:00pm Break

11:35 - 12:35pm Lunch

Yerba Buena Salon 93:00 - 5:00pm AFTERNOON JOINT SESSION3:00 - 3:30pm Keynote Presentation: Gregory Armstrong3:30 - 4:00pm Keynote Presentation: E. Antonio Chiocca5:30 - 7:30pm Town Hall Meeting: Hot Topics in Neuro-Oncology Yerba Buena Salon 97:30 - 8:30pm Young Investigator’s Career Development and Networking Session Yerba Buena Salon 77:30 - 10:30pm WELCOME RECEPTION City View at the Metreon (See map, page 11)

Friday, November 17, 2017 Main Meeting Program

ASNO/SNO Joint Session: New Horizons in PET Imaging in Neuro-oncology

Current Update on the Diagnosis and Management of Lower Grade Gliomas

A “Vagabond Theory” of Glioblastoma: Picking One’s Way Through the Brain Microenvironment to Fatal Progression

Therapeutic Opportunities Presented by Dysregulated Cell Signaling Mechanisms

Yerba Buena 1-3 Yerba Buena 7 Yerba Buena 9 Yerba Buena 10-12 Yerba Buena 8 Yerba Buena 4-6

Immune Based Therapies for Glioma

Getting More Out of Radiation: Combination Therapy and Dose Escalation

Yerba Buena Salons 7-99:00 - 12:00pm MORNING PLENARY SESSION 9:05 - 9:35am Keynote Presentation: W.K. Alfred Yung9:35 - 10:05am Keynote Presentation: Walter Koroshetz10:05 - 10:35am Keynote Presentation: Ludmil Alexandrov

1:30 - 3:00pm CONCURRENT SESSION 2A: Adult Clinical Trials I

3:00 - 3:15pm Break

3:15 - 5:00pm CONCURRENT SESSION 3A: Adult Clinical Trials II

1:30 - 3:00pm CONCURRENT SESSION 2B: Surgery/Radiation/ Radiobiology

3:00 - 3:15pm Break

3:15 - 5:00pm CONCURRENT SESSION 3B: Epigenetics/Genetics

1:30 - 3:00pm CONCURRENT SESSION 2C: Experimental Therapeutics and Tumor Models

3:00 - 3:15pm Break

3:15 - 5:00pm CONCURRENT SESSION 3C: Microenvironment/ Angiogenesis/Invasion

Yerba Buena Salon 9 Yerba Buena Salon 8 Yerba Buena Salon 7

5:30 - 7:30pm Independent Supported Symposia7:30 - 9:30pm E-TALKS Golden Gate C1/C2/C37:30 - 9:30pm POSTER SESSION Golden Gate AB

7:00 - 8:30am SUNRISE SESSIONS

Yerba Buena Salon 9

10:35 - 10:50am Break

10:50 - 11:50am Top Scoring Abstracts11:50 - 11:55am Memorial Tribute to Jan Esenwein11:55 - 12:00pm Jan Esenwein Public Service Award

12:15 - 1:15pm Lunch - Lunchtime Tutorials and Educational Sessions / Independent Supported Symposia


P R O G R A M AT A G L A N C ESaturday, November 18, 2017 Main Meeting Program

Yerba Buena Salons 7-99:00 - 12:00pm MORNING PLENARY SESSION9:05 - 9:35am Keynote Presentation: Jennifer Doudna9:35 - 10:05am Keynote Presentation: Carlo Croce

10:05 - 10:35am Victor Levin Award

10:35 - 10:50am Break

10:50 - 11:20am Presidential Address11:20 - 11:25am Lifetime Achievement Award11:25 - 11:30am Platinum Supporter Awards11:30 - 12:00pm Late Breaking Abstracts

12:15 - 1:15pm Lunch - Lunchtime Tutorials and Educational Sessions / Independent Supported Symposia

1:30 - 3:15pm CONCURRENT SESSION 5A: Metabolomics/Cell Biology/ Cell Signaling

3:15 - 3:30pm Break

3:30 - 5:00pm CONCURRENT SESSION 6A: CNS Metastases

1:30 - 3:15pm CONCURRENT SESSION 5B: Practical and Applied Neuro-Oncology I

3:15 - 3:30pm Break

3:30 - 5:00pm CONCURRENT SESSION 6B: Practical and Applied Neuro-Oncology II

1:30 - 3:15pm CONCURRENT SESSION 5C: Imaging

3:15 - 3:30pm Break

3:30 - 5:30pm CONCURRENT SESSION 6C: RANO Update

Yerba Buena 9 Yerba Buena 8 Yerba Buena 7

5:00 - 7:00pm E-TALKS Golden Gate C1/C2/C35:00 - 7:00pm POSTER SESSION Golden Gate AB5:00 - 7:00pm EVENING SURVIVORSHIP SESSION Nob Hill

7:00 - 11:00pm SNO GALA AT&T Park (separate ticket required)

Sunday, November 20, 2016 Main Meeting Program

8:30 - 10:10am CONCURRENT SESSION 7A: Pediatrics - Clinical

10:10 - 10:20am Break

10:20 - 12:00pm CONCURRENT SESSION 8A: Pediatrics - Basic Science

8:30 - 10:10am CONCURRENT SESSION 7B: Molecular Pathology - Adult and Pediatric

10:10 - 10:20am Break

10:20 - 12:00pm CONCURRENT SESSION 8B: Stem Cells

8:30 - 10:10am CONCURRENT SESSION 7C: Immunology - Preclinical and Clinical I

10:10 - 10:20am Break

10:20 - 12:00pm CONCURRENT SESSION 8C: Immunology - Preclinical and Clinical II

Yerba Buena 9 Yerba Buena 8 Yerba Buena 7

Yerba Buena 712:00 - 12:30pm HIGHLIGHTS OF SNO 2017 Presenters: Manish Aghi, Frank Furnari, Vinay Puduvalli

12:30pm Meeting Adjourn

Novel Metabolic Targets and Their Genetic Basis in Glioma

Brain Metastases

EANO/SNO: Glioblastoma in the Elderly: Solid Conclusions Built on Shifting Sand?

Histone Mutations in Pediatric Gliomas

Yerba Buena 9 Yerba Buena 4-6 Yerba Buena 10-12 Yerba Buena 8 Yerba Buena 7 Yerba Buena 1-3

Using Patient Reports as a Measure of Net Clinical Benefit

Joint AAN/SNO Session: Tumor Related Epilepsy


Circulating Biomarkers - Technology and Application

Meningiomas: Molecular Advances Toward Developing Targeted Therapies

Clonal Evolution of Adult and Pediatric Glioma

Discovery, Characterization and Functionalizing Novel Glioma Genes

Yerba Buena 9 Yerba Buena 8 Yerba Buena 4-6 Yerba Buena 1-3 Yerba Buena 10-12 Yerba Buena 7

Viral Therapy: Advances from Bench to Bedside

Developing Cancer Stem Cell Targeting Strategies


E D U C AT I O N D AY P R O G R A MThursday, November 16, 2017

Education Day Co-chairs: Susan Bell, Robert Cavaliere, Albert Kim, Khalid Shah Supported by the American Brain Tumor Association and Celgene

7:00-8:00am LIGHT CONTINENTAL BREAKFAST Yerba Buena Foyer

CONCURRENT BREAKOUT SESSIONTUMOR BIOLOGY AND THERAPYYerba Buena Salon 9

Biology of ResistanceModerators: Albert Kim, Khalid Shah

9:30-9:55am Intrinsic vs. acquired resistance in cancer Maurizio Scaltriti

9:55-10:20am Subclonal architecture and therapeutic implications in glioblastoma Albert Kim

10:20-10:45am The impact of tumor metabolic reprogramming on therapeutic resistance Paul Mischel

10:45-11:10am Immune resistance and suppression mechanisms in brain tumors Gavin Dunn

11:10-11:35am Role of macrophages and microglia in tumor progression David Gutmann

11:35-12:35pm LUNCH Yerba Buena Foyer

CONCURRENT BREAKOUT SESSIONPRACTICAL AND APPLIED NEURO-ONCOLOGYYerba Buena Salon 8

Survivorship and Measuring Outcomes Moderators: Susan Bell, Robert Cavaliere

9:30-9:55am Survivorship and brain tumors: wishful thinking or a daily reality? Robert Cavaliere

9:55-10:20am Application and interpretation of patient reported outcomes in clinical research Jeffrey A. Sloan

10:20-10:45am SISAQOL initiative in neuro-oncology Martin Taphoorn

10:45-11:10am Development and implementation of neuro- oncology survivorship care plans Heather Leeper

11:10-11:35am Quality of life issues in meningioma patients Linda Dirven

MORNING JOINT SESSION Yerba Buena Salon 9

8:00-8:10am Welcome and Introduction Susan Bell, Robert Cavaliere, Albert Kim, Khalid Shah

8:10-8:40am Keynote Presentation: Emerging principles of therapeutic resistance in cancer Trever Bivona

8:40-9:10am Keynote Presentation: Integrative cancer care Donald I Abrams

9:10-9:30am BREAK Yerba Buena Foyer


E D U C AT I O N D AY P R O G R A MThursday, November 16, 2017

AFTERNOON JOINT SESSION Yerba Buena Salon 9

3:00-3:30pm Keynote Presentation: Impact of self-reported outcomes on early detection of late effects among survivors of childhood cancer Gregory Armstrong

3:30-4:00pm Keynote Presentation: Different facets of resistance and their implications on the future of neuro-oncology E. Antonio Chiocca

4:00-4:30pm Panel Discussion: Therapy resistance Trever Bivona, Paul Mischel, Maurizio Scaltriti, Jann Sarkaria

4:30-5:00pm Panel Discussion: Burnout in neuro-oncology practitioners Terri Armstrong, Shlomit Yust-Katz, Alvina Acquaye

5:00pm ADJOURN

AFTERNOON CONCURRENT BREAKOUT SESSION TUMOR BIOLOGY AND THERAPY

Therapy-specific Resistance MechanismsModerators: Albert Kim, Khalid ShahYerba Buena Salon 9

12:35-1:00pm Understanding TMZ resistance and advancing strategies for sensitization in glioblastoma Jann Sarkaria

1:00-1:25pm Molecular mechanisms of resistance to anti- angiogenic therapy in glioblastoma Manish Aghi

1:25-1:50pm Principles of radiation resistance in glioblastoma Erik Sulman

1:50-2:15pm Molecular mechanisms of resistance to immune checkpoint inhibitors Roger Lo

2:15-2:40pm Overcoming tumor resistance via engineering novel biological therapies Khalid Shah

2:40-3:00pm BREAK Yerba Buena Foyer

AFTERNOON CONCURRENT BREAKOUT SESSION PRACTICAL AND APPLIED NEURO-ONCOLOGY

Mitigating Effects of Treatment and Disease Moderators: Susan Bell, Robert CavaliereYerba Buena Salon 8

12:35-1:00pm Ketogenic diet in the management of brain tumors Adrienne Scheck

1:00-1:25pm Nutrition for cancer patients Leonora Renda

1:25-1:50pm Current landscape of otoprotection chemotherapy-induced ototoxicity Susan Lindemulder

1:50-2:15pm Sleep and wake disturbances, fatigue and insomnia in cancer patients Ann Berger

2:15-2:40pm Care of the caretaker Suzanne Kisylia


5:30-7:30pm TOWN HALL MEETING: HOT TOPICS IN NEURO-ONCOLOGY Yerba Buena Salon 9 Light refreshments at 5:30pm Moderator: David Gutmann

• Tumor Treating Fields, Roger Stupp, Michael Weller• Bevacizumab-how is it being used? Timothy Cloughesy, Martin van den Bent• Integrative Medicine, Elena Ladas, Adrienne Scheck

Young Investigator’s Career Development and Networking Session Yerba Buena Salon 7(Pre-registration required)

WELCOME RECEPTION City View at the Metreon (See map, page 11)

7:30-8:30pm

7:30-10:30pm


6:45-9:00am LIGHT CONTINENTAL BREAKFAST Yerba Buena Foyer & Golden Gate Foyer

7:00-8:30am SUNRISE SESSIONS

M A I N M E E T I N G P R O G R A MFriday, November 17, 2017

ASNO/SNO Joint Session: New Horizons in PET Imaging in Neuro-oncology Shin-Ichi Miyatake (Chair)Yerba Buena Salons 1-3

• Role of PET imaging for decision making in meningiomasJoerg-Christian Tonn

• Usefulness of positron emission tomography (PET) for CNS tumorsKeisuke Miyake

• Feedback of the PET-imaging to the treatment of malignant brain tumors and radiation injuriesShin-Ichi Miyatake

• Simultaneous PET/MRI in clinical neuro-oncologyIan Law

A “Vagabond Theory” of Glioblastoma: Picking One’s Way Through the Brain Microenvironment to Fatal Progression Michael Berens (Chair)Yerba Buena Salon 7

• From niche to milieuMichael Berens

• What got you here, won’t get you thereJoanna Phillips

• Cloak and daggerJustin Lathia

• Inside out-the making of the microenvironment of glioblastomaJakub Godlewski

Immune Based Therapies for GliomaDuane Mitchell (Chair)Yerba Buena Salon 9

• Cellular immunotherapy targeting glioblastomaDuane Mitchell

• Checkpoint inhibitors for malignant gliomasMichael Lim

• Immunotherapy targeting glioma neoantigensHideho Okada

• Overcoming immunosuppression in malignant gliomasDerek Wainwright

Therapeutic Opportunities Presented by Dysregulated Cell Signaling MechanismsFrank Furnari (Chair)Yerba Buena Salons 10-12

• Leaders and followers in brain tumor heterogeneityFrank Furnari

• Regulatory circuits in GBM subtypesShi-Yuan Cheng

• Next-generation therapies to treat driver pathways in glioblastomaWilliam Weiss

• Metabolic signaling and epigenetic regulation in gliomaZhimin Lu

Current Update on the Diagnosis and Management of Lower Grade GliomasDaniel Brat (Chair)Yerba Buena Salon 8

• Contemporary molecular classification of lower grade gliomas with implications for diagnosis and gradingDaniel Brat

• Intraoperative IDH status determining extent of resection and outcomeGelareh Zadeh

• 2HG imaging: A window in the biology and natural history of IDH-mutant low grade gliomasElizabeth Maher

• Ancestry of multifocal lower grade gliomasJoseph Costello

Getting More Out of Radiation: Combination Therapy and Dose EscalationErik Sulman (Chair)Yerba Buena Salons 4-6

• Mechanisms to improve the effect of radiationErik Sulman

• The blood brain barrier and radiosensitizers - what we do and don’t knowJann Sarkaria

• Metabolic image guided dose escalation radiation therapyChristina Tsien

• Multi-arm adaptive trials to improve the efficacy of radiationBrian Alexander

6:00-7:00am MORNING YOGA Foothill C soc-neuro-onc.org/SNO/SNOCares soc-neuro-onc.org/SNO/SNOCares




Scientific Meeting Co-Chairs: Manish Aghi, Frank Furnari, Vinay Puduvalli

9:00-12:00pm FRIDAY PLENARY SESSION Yerba Buena Salons 7-9

9:00-9:05am Welcome and Introduction of Scientific Program Manish Aghi, Frank Furnari, Vinay Puduvalli

9:05-9:35am Keynote Presentation: Introduction to the Moonshot Program W.K. Alfred Yung

9:35-10:05am Keynote Presentation: Advancing science from discovery lab to strategic teamwork: an NINDS perspective Walter Koroshetz

10:05-10:35am Keynote Presentation: Signatures of mutational processes in human cancer Ludmil Alexandrov

10:35-10:50am BREAK Yerba Buena Foyer & Golden Gate Foyer

10:50-11:05am Mutant IDH1 co-operates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in gliomaCSIG-08 Mukherjee J, Johannessen T, Ohba S, Chow T, Jones L, Pandita A, Pieper R ADULT BASIC RESEARCH AWARD AND ANDREW PARSA YOUNG INVESTIGATOR AWARD Supported by the National Brain Tumor Society

11:05-11:20am Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed ACTR-58 MGMT-methylated glioblastoma patients: the CeTeG/NOA-09 trial Herrlinger U, Tzaridis T, Mack F, Steinbach J, Schlegel U, Sabel M, Hau P, Kortman R, Krex D, Grauer O, Goldbrunner R, Schnell O, Baehr O, Uhl M, Tabatabai G, Ringel F, Schmidt-Graf F, Brehmer S, Weyerbrock A, Bullinger L, Vajkoczy P, Vatter H, Schäfer N, Kebir S, Weller J, Stummer W, Simon M, Keil V, Nelles M, Fimmers R, Pietsch T, Hattingen E, Coch C, Glas M ADULT CLINICAL RESEARCH AWARD

11:20-11:35am AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: ACTR-46 updated results from the phase 1 non-enhancing glioma population Mellinghoff I, Touat M, Maher E, De La Fuente M, Cloughesy T, Holdhoff M, Cote G, Burris H, Janku F, Huang R, Young R, Ellingson B, Nimkar T, Jiang L, Ishii Y, Choe S, Fan B, Steelman L, Yen K, Bowden C, Pandya S, Wen P ADULT CLINICAL RESEARCH AWARD Supported by the American Brain Tumor Association

11:35-11:50am Comprehensive genomic characterization of aggressive meningiomas identifies molecular signatures that predict GENE-04 clinical outcomes Vasudevan H, Braunstein S, Phillips J, Pekmezci M, Wu A, Reis G, Magill S, Chang S, Sneed P, McDermott M, Perry A, Raleigh D ADULT BASIC RESEARCH AWARD Supported by the Brain Tumour Charity

11:50-11:55am Memorial Tribute to Jan Esenwein: Charles Haynes

11:55-12:00pm Jan Esenwein Public Service Award Recipient: Carol Kruchko

12:15-1:15pm LUNCH Yerba Buena Foyer & Golden Gate Foyer

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONSNot sponsored by The University of Texas MD Anderson Cancer Center

Neuro-Oncology Trainee Forum Nob Hill CDJennifer Clarke, Sylvia Eisele, Na Tosha Gatson, Kait Nevel (Chairs), Vinay Puduvalli (Advisor)• Fellowship application - taking the Match by the Horns, Scott R. Plotkin• Neuro-Oncology career search - avoiding pitfalls and accurately gauging your needs against what programs

have to offer, Vinay Puduvalli• Early Career Development- working through challenges and adding value to your new institution, Javier Gonzalez


12:15-1:15pm LUNCH, continued

Palliative Care-Health Outcome Measures and Communication Strategies in Neuro-Oncology Tobias Walbert (Chair) Nob Hill AB• Introduction to palliative care in neuro-oncology and health outcome measures, Tobias Walbert• Communication strategies in neuro-oncology, Alan Carver• Palliative care integration into neuro-oncology, Jennifer Philip

Emerging Functional and Genomic Single Cell Technologies Yerba Buena Salons 4-6Keith Ligon (Chair)• Single cell mass as a novel biomarker of drug response in brain tumors, Keith Ligon• Single cell cloning analysis of tumors and their treatment hierarchies using optical bar coding, Katrin Lamszus• EvoSeq: A molecular time machine to characterize resistance at a single cell level, Pratiti “Mimi” Bandopadhayay

Clinical Trials - A Primer for Junior Investigators Yerba Buena Salons 1-3Patrick Wen (Chair)• Design of phase 0 and I trials, Patrick Wen• Design of phase II trials, Timothy Cloughesy• Basic statistics for clinical trial design, Karla Ballman

Epigenetics of CNS Malignancies Yerba Buena Salons 10-12Houtan Noushmehr (Chair)• Defining the non-coding epigenome of glioma CpG island methylator phenotype (G-CIMP), Houtan Noushmehr• Disentangling developmental and oncogenic epigenetic states of medulloblastoma subtypes, Paul Northcott• Histone modifications in pediatric gliomas, Sriram Venneti

Industry Supported Symposia Yerba Buena Salons 13-15Not sponsored by The University of Texas MD Anderson Cancer Center • Incorporating new strategies: current and future directions in glioblastoma management


1:30-5:00pm CONCURRENT SESSIONS

CONCURRENT SESSION 2AAdult Clinical Trials I Moderators: Timothy Cloughesy, Warren MasonYerba Buena Salon 9

1:30-1:40pm Introduction Burt Nabors

1:40-1:55pm Multicenter, phase 2 study of bevacizumab RARE-19 in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: an NF Clinical Trials Consortium study Plotkin S, Tonsgard J, Ullrich N, Allen J, Blakeley J, Rosser T, Campian J, Clapp W, Fisher M, Cutter G, Korf B, Packer R, Thomas C, Karajannis M

1:55-2:10pm Full enrollment results from the phase ACTR-71 1/2, multicenter, open-label study of marizomib (MRZ) ± bevacizumab (BEV) in recurrent WHO grade IV malignant glioma (glioblastoma, rGBM) Bota D, Desjardins A, Mason W, Kesari S, Magge R, Winograd B, Reich S, Levin N, Trikha M

2:10-2:25pm Intravenous delivery of Toca 511 in patients ATIM-21 with high grade glioma results in quantifiable expression of cytosine deaminase in tumor tissue Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T

2:25-2:40pm Dose dense temozolomide (TMZ) as initial ACTR-06 treatment for high-risk oligodendroglial tumors: long-term results of a Phase II AINO (Italian Association for Neuro-Oncology) study Soffietti R, Pellerino A, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bello L, Rudà R

2:40-2:50pm Hypoxia activated evophosphamide (TH-302)ACTR-95 for recurrent GBM following bevacizumab failure, a multicenter phase II study Brenner A, Reardon D, Wen P, Fox P, Huang S, Muzi M, Liu Y, Lee E

2:50-3:00pm Predictive significance of IDH1/2 mutation ACTR-37 and 1p/19q co-deletion status in a post-hoc analysis of NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high risk low-grade gliomas Bell E, Zhang P, Shaw E, Buckner J, Barger G, Coons S, Bullard D, Mehta M, Gilbert M, Brown P, Stelzer K, Fleming J, McElroy J, Timmers C, Becker A, Salavaggione A, Liu Z, Aldape K, Brachman D, Gertler S, Murtha A, Schultz C, Johnson D, Shu H, Chakravarti A

3:00-3:15pm BREAK Yerba Buena & Golden Gate Foyers




CONCURRENT SESSION 2BSurgery/Radiation/RadiobiologyModerators: Fen Xia, Bradley ElderYerba Buena Salon 8

1:30-1:40pm A comprehensive genomic landscape of gliomaTMOD-04 spheroid cultures recapitulates the heterogeneity of glioblastoma and identifies DNA methylation predictors of radiotherapy response Wang Q, Ezhilarasan R, Goodman L, Eskilsson E, Yang J, Gumin J, Zheng S, Tang M, Jaffari M, Long L, Yoshihara K, Sun P, Heffernan T, Yung W, Draetta G, Aldape K, Lang F, Verhaak R, Sulman E

1:40-1:50pm A 40-year multi-institutional review of RTHP-31 intracranial germ cell tumors in adolescents and young adult Lo A, Goddard K, Hodgson D, Dang J, Tyldesley S, Bouffet E, Bartels U, Cheng S, Hukin J, Bedard P, Tran J, Laperriere N

1:50-1:55pm Patient outcomes and factors associated RTHP-25 with receipt of proton radiation therapy for adults with primary gliomas: analysis of the National Cancer Data Base Jhaveri J, Cheng E, Liu Y, Ferris M, Chowdhary M, Morgan T, Gillepsie T, Olson J, Valoschin A, Eaton B, McDonald M, Shu H-K, Curran W, Patel K

1:55-2:00pm Convection enhanced delivery of topotecan SURG-10 and gadolinium for recurrent GBM via the Cleveland Multiport Catheter: A first in human study Vogelbaum M, Mohammadi A, Brewer C, Peereboom D, Ahluwalia M

2:00-2:05pm CSF-1R inhibition ameliorates radiation-RBIO-03 induced memory loss in a rodent glioma model Feng X, Grue K, Liu S, Gupta N, Rosi S

2:05-2:10pm The impact of surgery in molecularly defined SURG-05 low-grade glioma: an integrated clinical, radiological and molecular analysis Wijnenga W, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J, Smits M, Gahrmann R, Rutten G, Verheul J, Fleischeuer R, Dirven C, Vincent A, van den Bent M

2:10-2:15pm Subcortical stimulation mapping of descendingSURG-03 motor pathways for perirolandic gliomas: Assessment of morbidity and functional outcome in over 700 patients Han S, Troncon I, Morshed R, Jordan K, Henry R, Berger M

2:15-2:20pm Pediatric radiation-induced glioblastoma: PDTM-01 transcriptomic and drug screening analysis of primary patient samples DeSisto J, Donson A, Flannery P, Lemma R, Sanford B, Foreman N, Vibhakar R, Jones K, Green A

2:20-2:25pm A prospective phase II randomized trial to ACTR-72 compare intensity modulated proton radiotherapy (IMPT) vs. intensity modulated radiotherapy (IMRT) for newly diagnosed Glioblastoma (GBM) Chung C, Brown P, McAvoy S, Grosshans D, Dibaj S, Guha-Thakurta N, Li J, McGovern S, Mcaleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, de Groot J, Heimberger A, Armstrong T, Gilbert M, Mahajan A, Wefel J

2:25-2:30pm TIE2-mediated epigenetic modifications GENE-19 regulate radioresistance of glioblastoma Hossain M, Shifat R, Rivera-Molina Y, Puerta- Martinez F, Jiang H, Kim D, Johnson D, Bedford M, Sulman E, Lang F, Fueyo J, Gomez-Manzano C

2:30-2:35pm Histopathologic features predict local control MNGI-09 after adjuvant radiotherapy for atypical meningioma Chen W, Magill S, Wu A, Vasudevan H, Aghi M, Theodosopoulos P, Perry A, McDermott M, Sneed P, Braunstein S, Raleigh D

2:35-2:40pm High-risk meningioma: Initial outcomes from MNGI-08 NRG Oncology/RTOG-0539 Rogers L, Zhang P, Vogelbaum M, Perry A, Ashby L, Modi J, Alleman A, Galvin J, Fogh S, Youssef E, Deb N, Kwok Y, Robinson C, Shu H, Fisher B, Panet-Raymond V, McMillan W, de Groot J, Mehta M

2:40-2:45pm Prognostic factors, treatment and outcome RARE-15 in patients with intracranial hemangioblastoma: a study of 3449 patients from the National Cancer Data Base Chan L, Bai H, Huang Y, Li X, Liao W, Cao Y, Karakousis G, Huang R, Xiao B, Zhang P, Yang L

2:45-2:50pm Feasibility and safety of surgical biopsy for PDCT-20 patients with DIPG: preliminary results from DIPG-BATS Gupta N, Goumnerova L, Ayyanar K, Gump W, Bendel A, Nagib M, Bowers D, Weprin B, Bredlau A, Gururangan S, Fuchs H, Cohen K, Jallo G, Dorris K, Handler M, Comito M, Dias M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Gardner S, Karajannis M, Harter D, Gauvain K, Limbrick D, Leonard J, Geyer J, Leary S, Browd S, Khatib Z, Ragheb J, Bhatia S, MacDonald T, Aguilera D, Brahma B, Manley P, Chi S, Mueller S, Banerjee A, Murray J, Nazemi K, Baird L, Robison N, Kiehna E, Krieger M, Sandler E, Aldana P, Wang J, Sood S, Neuberg D, Puligandla M, Greenspan L, Wright K, Prados M, Bandopadhayay P, Ligon K, Kieran M

2:50-2:55pm Results of phase I of the PARADIGM trial: ACTR-22 a phase I dose escalation study of olaparib in combination with short course radiotherapy in elderly patients with newly diagnosed glioblastoma (GBM) Chalmers A, Stobo J, Short S, Herbert C, Saran F, Morris A, Dillon S, Kelly C

2:55-3:00pm Discussion

3:00-3:15pm BREAK Yerba Buena Foyer & Golden Gate Foyer



CONCURRENT SESSION 2CExperimental Therapeutics and Tumor ModelsModerators: William Weiss, Jann SarkariaYerba Buena Salon 7

1:30-1:35pm Discovery of CT-179: a small molecule EXTH-08 inhibitor of the OLIG2 transcription factor with potent anti-tumour activity in high- grade glioma Johns T

1:35-1:40pm PLX51107, a novel bromodomain inhibitor, PDTM-15 works synergistically with AURORA-A kinase inhibitor MLN8327 in treating MYC- amplified medulloblastoma Wadhwa E, Zhang J, Powell B, Van C, Gustafson C, Nicolaides T 1:40-1:45pm Zika virus targeting of malignant human and EXTH-01 murine brain tumors Shiao M, Bierle C, Chrostek M, Crane A, Danczyk G, Miller Z, Pearce C, Schaible K, Schleiss M, Sipe C, Straub E, Toman N, Vaid S, Voth J, Low W

1:45-1:50pm Combined intracavitary thermotherapy SURG-32 with iron-oxide nanoparticles and radiotherapy as a promising treatment modality in recurrent GBM Grauer O, Jaber M, Hess K, Weckesser M, Maring S, Schwindt W, Stummer W, Wölfer J

1:50-1:55PM MEK kinase inhibitor, trametinib, suppresses EXTH-17 macrophage-secreted TNF-α on oncolytic HSV-1 therapy, enhancing virotherapy Yoo J, Lee T, Liu J, Jaime-Ramirez A, Weiss A, Russell L, Nallanagulagari T, Zhang J, Kaur B 1:55-2:00pm GD2-directed chimeric antigen receptor T PDTM-39 cells as a potent immunotherapy regimen in xenograft models of diffuse intrinsic pontine glioma Mount C, Majzner R, Sundaresh S, Arnold E, Kadapakkam M, Monje-Deisseroth M, Mackall C

2:00-2:05pm A precision medicine approach to target EXTH-46 EGFRvIII in GBM: Osimertinib (AZD9291) inhibits the growth of EGFRvIII-positive glioblastoma stem cells and increases survival of mice bearing intracranial EGFRvIII- positive GBM Kwatra M, Nanni C, Roberts C, Kwatra S, Gilbert M, Lesser G

2:05-2:10pm Application of a functional genetics approach DDIS-21 to identify pharmacological inhibitors of HIF-1 α Qi Q, Johannessen T-C, Wang J, Li X, Bjerkvig R, Prestegarden L

2:10-2:15pm TG02, a novel targeting of transcription and EXTH-62 metabolism in glioblastoma Su Y, Chen R, Song H, Zhang Q, Li A, Celiku O, Meetze K, Estok T, Maric D, Zhuang Z, Yang C, Zhang W, Gilbert M, Wu J

2:15-2:20pm A cancer drug-atlas enables prediction of EXTH-06 parallel drug vulnerabilities Narayan R, Molenaar P, Cornelissen F, Roelofs I, Sminia P, Wurdinger T, Koster J, Westerman B

2:20-2:25pm An engineered microRNA cluster for broad EXTH-69 targeting of epigenetic complexes in GBM Bhaskaran V, Idriss M, Lawler S, Chiocca E, Peruzzi P

2:25-2:30pm Differentiated pharmacology of the EXTH-43 imipridone ONC201, the first selective DRD2/3 antagonist in clinical neuro-oncology Madhukar N, Prabhu V, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free R, Sibley D, Allen J

2:30-2:35pm Imaging glioblastoma stem cells with EXTH-75 7-amino acid-length tumor-homing peptide identified by phage display biopanning Kim J, Rich J, Liu J

2:35-2:40pm Human pluripotent stem cell-based models TMOD-09 of neuroblastoma Huang M, Zheng T, Guo J, Sperring C, Miller M, McHenry L, Zhen Q, Moriarity B, Bronner M, Conklin B, Largaespada D, Maris J, Matthay K, Weiss W

2:40-2:45pm MYCN overexpression and stabilization drives TMOD-05 medulloblastoma from human neuro- epithelial stem cells Čančer M, Hutter S, Rosén G, Hellström A, Essand M, Huang M, Tailor J, Smith A, Weiss W, Falk A, Weishaupt H, Swartling F

2:45-2:50pm Pre-clinical safety and efficacy studies of STEM-32 neural stem cell mediated carboxylesterase/ irinotecan enzyme/prodrug gene therapy for recurrent glioma leading to first-in-human phase I clinical trial Ghoda L, Metz M, Tirughana R, Aramburo S, Gilchrist M, Gutova M, Synold T, Barish M, Brown C, D’Apuzzo M, Moats R, Potter P, Blanchard S, Portnow J, Aboody K






CONCURRENT SESSION 3AAdult Clinical Trials IIModerators: David Piccioni, Mustafa KhasrawYerba Buena Salon 9

3:15-3:20pm Therapeutic targeting of tumorigenic IMMU-03 EphA2+/EphA3+ brain tumor initiating cells with bispecific antibody in human glioblastoma Qazi M, Vora P, Venugopal C, Gorelik M, Singh M, Hu A, Subapanditha M, Chokshi C, Savage N, Yelle N, Adams J, Moffat J, Sidhu S, Singh S

3:20-3:25pm A phase I trial of hypofractionated ATIM-18 stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab in patients with recurrent high grade glioma (NCT02313272) Sahebjam S, Forsyth P, Arrington J, Jaglal M, Tran N, Etame A, Wicklund M, Drury-Sibiga A, Long W, Evernden B, Gatewood T, Macaulay R, Chinnaiyan P, Yu M

3:25-3:30pm Multicenter pilot study of radio-RARE-10 chemotherapy as first-line treatment for adults with medulloblastoma – the NOA-07 trial Beier D, Proescholdt M, Pietsch T, Jones D, Pfister S, Hattingen E, Dirven L, Lürding R, Weller M, Kortman R, Bogdahn U, Hau P

3:30-3:35pm A phase 1, multicenter, open-label study of ACTR-45 marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM) Bota D, Mason W, Kesari S, Piccioni D, Aregawi D, Desjardins A, Winograd B, Reich S, Levin N, Trikha M

3:35-3:40pm Final results from a phase I study of ACTR-76 plerixafor and bevacizumab in recurrent high-grade glioma Lee E, Muzikansky A, Gerstner E, Kuhn J, Reardon D, Nayak L, Norden A, Doherty L, Stefanik J, Armitage J, LaFrankie D, Ruland S, Vardam T, Stokes D, Smith K, McCluskey C, Gaffey S, Batchelor T, Jain R, Duda D, Wen P

3:40-3:45pm Durable responses observed in IDH1 wildtypeATIM-02 and mutant recurrent high grade glioma (rHGG) with Toca 511 & Toca FC treatment Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen C, Kalkanis S, Lai A, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago O, Hogan D, Jolly D, Wood K, Yang L, Gruber H, Das A, Walbert T

3:45-3:50pm Concordance of EGFR and MGMT analyses ACTR-68 between local and central laboratories: implications for clinical trial design and precision medicine for depatuxizumab- mafodotin (ABT-414) in glioblastoma (GBM) Lassman A, Dimino C, Mansukhani M, Murty V, Ansell P, Bain E, Holen K, Roberts-Rapp L, Lee J, Curran W, Mehta M, Canoll P

3:50-3:55pm Clinical impact of TERT promoter detection in ACTR-52 circulating cell-free DNA of patients with glioblastoma – a pilot study Juratli T, Stasik S, Richter S, Zolal A, Schackert G, Krex D, Thiede C

3:55-4:00pm Plasma and tumor pharmacokinetics of ACTR-67 Ribociclib in patients with recurrent glioblastoma Tien A, Bao X, DeRogatis A, Higginbotham L, Honea N, Mehta S, Li J, Sanai N 4:00-4:05pm A phase II study of the efficacy of ACTR-88 hypofractionated radiation therapy with bevacizumab and temozolomide followed by maintenance temozolomide and bevacizumab for recurrent high-grade gliomas Dixit K, Kumthekar P, Kruser T, Sachev S, Kalapurakal J, Gondi V, Grimm S, Nicholas M, Lukas R, Chmura S, Mehta M, Raizer J

4:05-4:10pm Does Levetiracetam act as a Ttmozolomide SURG-30 chemosensitizer in patients with glioblastoma? Roh T, Kim S, Kang S, Kim E, Cho J, Suh C, Chang J

4:10-4:15pm Results of the OPARATIC trial: a phase I dose ACTR-16 escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM) Chalmers A, Cruickshank G, Dunn L, Erridge S, Godfrey L, Herbert C, Jefferies S, Lopez J, McBain C, Pittman M, Sleigh R, Watts C, Webster-Smith M, Halford S

4:15-4:20pm Compliance and treatment duration predict ACTR-27 survival in a phase 3 EF-14 trial of tumor treating fields with temozolomide in patients with newly diagnosed glioblastoma Ram Z, Kim C, Nicholas G, Toms S

4:20-4:25pm Advanced MRI assessment during dendritic NIMG-25 cell immunotherapy Eoli M, Cuccarini V, Aquino D, Anghileri E, Pellegatta S, Finocchiaro G, Bruzzone M

4:25-4:30pm A phase I study of MLN0128 (TAK-228) and ACTR-93 bevacizumab in patients with advanced solid tumors including glioblastoma Nayak L, Hays J, Do K, Muzikansky A, Gaffey S, Lee E, Rinne M, Norden A, Beroukhim R, Puduvalli V, Wen P, Doyle L, Chen H, Shapiro G, Reardon D

4:30-4:35pm Safety and efficacy evaluation of a phase II ACTR-53 study of bortezomib in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme (GBM) Kong X, Nguyen N, Choi Y, Zhang G, Nguyen H, ilka E, Green S, Yong W, Liau L, Kaprealian T, Pope W, Nghiemphu P, Cloughesy T, Lassman A, Lai A



4:35-4:40pm Final results from the dose-escalation stage ACTR-28 of a Phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma Goldlust S, Nabors L, Mohile N, Benkers T, Hsu S, Silberman S, Singer S, Rao M, Cappello L, Farmer G

4:40-4:45pm Molecular genetic, host-derived and clinical ACTR-23 determinants of long-term survival in glioblastoma: first results from the Brain Tumor Funders’ Collaborative Consortium Happold C, Felsberg J, Clarke J, Soffietti R, Marosi C, Krex D, Ducray F, Hau P, Reijneveld J, Weyerbrock A, Wick A, Reardon D, Glas M, Razis E, Herrlinger U, Tonn J, Carpentier A, Lefranc F, Le Rhun E, Verschuere T, Golfinopoulos V, Klein M, Reifenberger G, Weller M

4:45-4:50pm Clinical evaluation of the imipridone ONC201 ACTR-51 in recurrent glioblastoma: Predictive and pharmacodynamic biomarker analyses Arrillaga-Romany I, Allen J, Prabhu V, Tarapore R, Zloza A, Oster W, Wen P, Batchelor T


CONCURRENT SESSION 3BEpigenetics/Genetics Moderators: Joseph Costello, Colin WattsYerba Buena Salon 8

3:15-3:30pm Transcription elongation factors represent in GENE-30 vivo cancer dependencies in glioblastoma Miller T, Liau B, Wallace L, Morton A, Xie Q, Dixit D, Factor D, Kim L, Morrow J, Wu Q, Mack S, Hubert C, Paddison P, Horbinski C, Bernstein B, Tesar P, Rich J

3:30-3:40pm Atrx deficiency in glioma cells of origin GENE-24 promotes disease-defining phenotypes by way of global epigenomic remodeling Danussi C, Bose P, Parthasarathy P, Silberman P, Van Arnam J, Vitucci M, Tang O, Heguy A, Chan T, Sulman E, Lang F, Creighton C, Deneen B, Miller C, Picketts D, Kannan K, Huse J

3:40-3:50pm Peripheral blood DNA methylation profiles GENE-02 identify IDH1/2 mutation status in adults with diffuse glioma Kloetgen A, Serrano J, Patel S, Bowman C, Shen G, Zagzag D, Karajannis M, Golfinos J, Placantonakis D, Tsirigos A, S. Chi A, Snuderl M

3:50-4:00pm A novel mutation in PRKCA is the major GENE-54 driver of Chordoid Gliomas Rosenberg S, Simeonova I, Bielle F, Verreault M, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella Branger D, Aubriot-Lorton M, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Mokhtari K, Pagnotta S, Iavarone A, Lasorella A, Huillard E, Sanson M

4:00-4:10pm Generation of a mouse model of diffuse GENE-17 intrinsic pontine glioma harboring ACVR1 G328V and H3.1 K27M mutations Mendez F, Nunez F, Koschmann C, Saxena M, Kamran N, Dzaman M, Pawar S, Lowenstein P, Castro M 4:10-4:20pm Emerging principles of synthetic lethality in GENE-12 glioblastoma Hoellerbauer P, Arora S, Feldman H, Carter L, Girard E, Corrin P, Olson J, Paddison P

4:20-4:25pm Characterizing epigenetic intratumoral GENE-59 heterogeneity in glioma using single- cell reduced representation bisulfite sequencing Johnson K, Tang M, Estecio M, Robson P, Verhaak R

4:25-4:30pm Epigenetic reprogramming in mutant IDH1 GENE-58 glioma impacts median survival, enhances DNA damage response and confers radioresistance Nunez FJ, Mendez FM, Kadiyala P, Savelieff M, Koschmann C, Carney S, Patel R, Manawar S, Kamran N, Saxena M, Ljungman M, Qin T, Sator M, Dzaman M, Venneti S, Hervey-Jumper S, Figueroa MD, Lowenstein PR, Castro MG

4:30-4:35pm The origin of human glioblastoma: Firework GENE-35 pattern glioblastoma genesis from subventricular zone Kang S, Lee J, Yoon S, Park J, Kim S, Kim E, Chang J

4:35-4:40pm Chromatin accessibility defines transcriptionalGENE-11 drivers of migration in human glioblastoma Tsankova N, Erfani P, Tome-Garcia J, Nudelman G, Tsankov A, Walsh M, Zaslavsky E

4:40-4:45pm Active chromatin regulatory maps identify GENE-32 core cell state drivers of glioblastoma Mack S, Wang X, Rich J

4:45-4:50pm Unanticipated germline cancer susceptibility GENE-39 mutations identified during routine next generation sequencing of primary CNS neoplasms Lord K, Smith R, Boman C, Patel G, Thatikonda S, Burnett M, Waldron J, Kemper C, Weinberg J, Groves M

4:50-4:55pm The 3D evolution and in vivo growth patterns GENE-33 of glioma cell populations Hilz S, Shelton S, Jalbert L, Wong H, Mazor T, Hong C, Hayes J, Luks T, Bengtsson H, Molinaro A, McDermott M, Berger M, Lim D, Diaz A, Phillips J, Chang S, Nelson S, Oldham M, Costello J




Industry Supported Symposium Yerba Buena Salons 13-15Not sponsored by The University of Texas MD Anderson Cancer Center • Neurosurgical Innovations for Treatment of Gliomas

5:30-7:30pm


7:30-9:30pm E-TALKS Interactive Electronic 4 Minute Presentations Followed By Group Discussions - Golden Gate C1/C2/C3 Group 1: Cell Signaling/Genetics/Epigenetics Golden Gate C1 Group 2: Drug Resistance/Experimental Therapeutics/Metabolism Golden Gate C2 Group 3: Imaging/Pediatrics/Outcomes/Practical & Applied Neuro-Oncology/Pathology Golden Gate C3

7:30-9:30pm POSTER SESSION Traditional Poster Viewing Golden Gate AB

CONCURRENT SESSION 3CMicroenvironment/Angiogenesis/InvasionModerators: Michael Berens, David GutmannYerba Buena Salon 7

3:15-3:30pm Microenvironment-derived mitochondria TMIC-18 prime glioma chemo-resistance by potentiated NAD metabolism and base excision DNA repair Liu Y, Gilbert M, Yang C

3:30-3:40pm Glioblastoma stem cells exploit the ANGI-17 alphavbeta8 integrin-TGFbeta signaling axis to drive tumor initiation and progression McCarty J, Sulman E, Rao G, Wang Q, Lang F, Guerrero P

3:40-3:50pm Genetic driver-mutations define the TMIC-02 tumors associated macrophage composition and function in glioblastoma Chen Z, Hambardzumyan D

3:50-4:00pm High resolution RNAseq profiling of ANGI-04 glioblastoma residual invasive cells isolated by a novel 5ALA fluorescence based method Rowlinson J, Estevez-Cebrero M, Lourdusamy A, Rahman R, Smith S

4:00-4:10pm Tumor-associated neutrophils promote TMIC-10 glioblastoma growth via osteopontin in a targetable manner Yagnik G, Nguyen A, Mueller S, Alvarado B, Watchmaker P, Kriegstein A, Diaz A, Aghi M

4:10-4:15pm Direct glioma blood vessel disruption improvesANGI-11 immune therapy but worsens anti-VEGF therapy Yadav V, Kadiyala P, Zamler D, Gutierrez A, Koschmann C, Castro M, Lowenstein P

4:15-4:20pm Reprogramming the brain tumor TMIC-12 microenvironment with hematopoietic stem and progenitor cells Wildes T, Flores C, Mitchell D

4:20-4:25pm A potent microglial response to blocking TMIC-04 the CD47-Sirpα anti-phagocytic axis overcomes deficient macrophage recruitment during anti- CD47 immunotherapy against glioblastoma Hutter G, Theruvath J, Graef C, Weissman I, Mitra S, Cheshier S

4:25-4:30pm Loss of host-derived osteopontin creates a TMIC-41 glioblastoma-promoting microenvironment Szulzewsky F, Schwendinger N, Güneykaya D, Cimino P, Hambardzumyan D, Synowitz M, Holland E, Kettenmann H

4:30-4:35pm Metabolic reprogramming of the glioma IMMU-37 microenvironment inhibits tumor immunosuppression Miska J, Muroski M, Rashidi A, Chang A, Zhang P, Han Y, Lesniak M

4:35-4:40pm IL11 secretion by glioblastoma associated DRES-15 microglia define a STAT3-MYC signaling axis that is suppressed in “exceptional responders” Li J, Kaneda M, Wang J, Akers J, Ramakrishnan V, Amirfakhri S, Hirshman B, Furnari F, Jiang T, Carter B, Glass C, Ren B, Varner J, Chen C

4:40-4:45pm IDH1 mutation regulates myeloid cells IMMU-58 mediated Immunosuppression in glioma Alghamri M, Kamran N, Nunez F, Lowenstein P, Castro M

4:45-4:50pm EGFR extracellular domain point mutant EXTH-56 A289V: A therapeutically targetable driver of glioblastoma invasion Thorne A, Binder Z, Bakas S, Wileyto E, Morrissette J, Akbari H, Rathore S, Scott A, Davatzikos C, O’Rourke D, Furnari F

4:50-4:55pm Extracellular milieu in recurrent human RBIO-01 gliomas: A repertoire for novel drug development Gupta K, Burns T




7:30-9:30pm E-TALKS - GROUP 1 Golden Gate C1

Cell Signaling/Genetics/EpigeneticsModerators: Milan Chheda, Renee Read

7:30pm FHL2 interacts with EGFRvIII to promote CSIG-19 glioblastoma growth Sun L, Lan Q, Li M

7:34pm Meningeal based tumors: role of STAT6 MNGI-06 expression Sahay A, Kadam V, Moiyadi A, Gupta T, Goda J, Shetty P, Jalali R, Epari S

7:38pm Pathway analysis of radiation-Induced MNGI-04 meningiomas reveals upregulation of inflammatory pathways in tumors with NF2- fusion Suppiah S, Agnihotri S, Yasin M, Zadeh G, Aldape K, Liu J

7:42pm Phosphoglycerate mutase 1 (PGAM1) CSIG-40 activates DNA damage repair via regulation of WIP1 activity Mukherjee J, Ohba S, Johannessen T, Kamalakar C, Pieper R

7:46pm miR-4516 is a novel prognostic marker and CBIO-20 promotes proliferation and invasion in glioblastoma Cui T, Bell E, McElroy J, Geurts M, Gulati P, Becker A, Fleming J, Yang L, Liu Z, Gray A, Robe P, Chakravarti A

7:50pm Use of decitabine to alter patterns of GENE-20 treatment-induced mutagenesis in glioblastoma Gallitto M, Pain M, Wang H, Deikus G, Sebra R, Yong R

7:54pm Brd4-bound stretch/super enhancer usage GENE-16 underlies sexual dimorphism in glioblastoma Kfoury N, Qi Z, Sankararaman S, Wilkinson M, Broestl L, Berrett K, Gertz J, Mitra R, Rubin J

7:58pm Discordant inheritance of chromosomal GENE-23 and extrachromosomal DNA elements contribute to dynamic disease evolution in glioblastoma deCarvalho A, Kim H, Poisson L, Koeman J, Mikkelsen T, Verhaak R

8:02pm Implications of spatial intratumoral GENE-05 mutational heterogeneity for precision medicine-guided treatment in newly diagnosed glioblastoma (GBM) Mahlokozera T, Vellimana A, Li T, Mao D, Zohny Z, Kim D, Tran D, Marcus D, Fouke S, Campian J, Dunn G, Miller C, Kim A

8:06pm Proline Glutamic acid and Leucine rich CSIG-03 Protein 1 (PELP1) Promotes Glioblastoma Progression via β-catenin Pathway” Sareddy GR, Zhou M, Liu J, Viswanadhapalli S, Gruslova A, Brann D, Brenner A, Vadlamudi R

8:10pm Chromothripsis leads to chromosomal GENE-44 rearrangements and gene fusions in primary glioblastomas Rousseau A, Coutolleau A, Menei P, Guardiola P, Boisselier B

8:14pm Clinical sensitivity and specificity of Illumina PATH-47 methylation array for classifying adult gliomas into WHO groups Eckel-Passow J, Decker P, Hughes E, Kollmeyer T, Kosel M, Burgenske D, Sarkaria J, Giannini C, Kipp B, Lachance D, Jenkins R

8:18pm Accurate detection of TERT promoter GENE-36 mutation in gliomas using Infinium DNA methylation arrays identifies novel epigenetic association Yang J, Wang Q, Long L, Ezhilarasan R, Sulman E

8:22pm IDH gene mutation status plays no impact on RTHP-17 survival in patients with glioblastoma at a first progression Tabei Y, Nagane M

8:26pm Clinical, molecular and radiological features PATH-12 of FGFR-TACC positive gliomas Di Stefano A, Savatovsky J, Bielle F, Alentorn A, Pïcca A, Saragoussi E, Villa C, Farina P, Lasorella A, Iavarone A, Sanson M

8:30-9:30pm Discussion in main poster area at designated flatscreen. Golden Gate B




7:30pm EZH2/PRC2-mediated epigenetic plasticity DRES-18 promotes therapeutic resistance by regulating STAT3 activation gene network in the glioma stem cells Park C, Atashi F, Caragher S, Baisiwala S, Lesniak M, James C, Ahmed A

7:34pm Primary resistance to EGFR inhibition in DRES-06 glioblastoma is mediated by a TNF-JNK-Axl- ERK signaling axis Guo G, Gong K, Habib A

7:38pm Activated Trk/Met pathway is a novel CSIG-32 resistance mechanism for CDK4/6 inhibitors that can be targeted with a specific small molecule inhibitor Olmez I, Purow B

7:42pm KIF11 as a novel therapeutic target in MNGI-01 meningioma Jungwirth G, Dettling S, Warta R, Lamszus K, Simon M, Unterberg A, Herold-Mende C

7:46pm RNA nanoparticle-based targeted gene EXTH-31 therapy for glioblastoma Lee TJ, Yoo JY, Kaur B, Croce C, Guo P

7:50pm Recurrent xenograft tumors upregulate EXTH-68 EGFR after lentiviral vector mediated suicide gene therapy for glioblastoma, but are resistant to combinatorial treatment with erlotinib Hossain J, Ystaas L, Latif A, Joseph J, Talasila K, Ninzima S, Riecken K, Fehse B, Bjerkvig R, Miletic H

7:54pm Oncolytic viral therapy with Delta24-RGD TMIC-03 induces a tumor-detrimental environment via phenotypic shift of macrophages van den Bossche W, Kleijn A, Teunissen C, Voerman J, Noske D, van Dongen J, Dirven C, Lamfers M

7:58pm The alkylating chemotherapeutic EXTH-14 temozolomide induces metabolic stress and potentiates NAD+ depletion-mediated cell death in IDH1 mutant cancers Tateishi K, Miller J, Higuchi F, V. A. Koerner M, Lelic N, Curry W, Batchelor T, Wakimoto H, S. Chi A, Cahill D

8:02pm Efficacy of the antibody-drug conjugate ABT-EXTH-39 414 in brain tumor models Muldoon L, McConnell H, Kersch C, Neuwelt E

8:06pm H3 K27M mutant gliomas are selectively EXTH-42 killed by ONC201, a small molecule inhibitor of dopamine receptor D2 Chi A, Stafford J, Sen N, Possemato R, Placantonakis D, Hidalgo ET, Harter D, Wisoff J, Golfinos J, Arrilaga-Romany I, Batchelor T, Wen P, Wakimoto H, Cahill D, Allen J, Oster W, Snude

8:10pm Development of a CRISPR-Cas9D10A DRES-04 targetable, high-complexity, single-cell barcoding approach for isolation of treatment resistant subclones from heterogenous malignant gliomas Zhang Z, Ezhilarasan R, Ding Y, Wang Q, Yang J, Long L, Verhaak R, Sulman E

8:14pm Combined use of the pan-IDH mutant EXTH-34 inhibitor AG-881 with radiation therapy shows added benefit in an orthotopic IDH1 mutant gliomma model in vivo Nicolay B, Narayanaswamy R, Amatangelo M, Aguado E, Nagaraja R, Murtie J, Liu G, Ishii Y

8:18pm Down-regulation of acetate metabolism METB-14 towards fatty acids in IDH1 mutant glioma Najac C, Radoul M, Viswanath P, Chaumeil M, Ronen S

8:22pm IDH3 promotes glioblastoma growth through CSIG-21 regulation of one carbon metabolism Stegh A

8:26pm GTP metabolic switch leads to nucleolar CBIO-12 transformation and malignant growth of glioblastoma Satoshi K, Hirayama A, Sakamoto N, Sumita K, Yoshino H, Warren M, Kawaguchi R, Ozawa T, Onishi N, Wolfe K, Okumura K, Ramkissoon A, Chow L, Malhotra A, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Anastasiou D, Wakimoto H, Bierhoff H, Horbinski C, Yasui W, Saya H, Soga T, Holland E, Grummt I, Mischel P, Sasaki A


Drug Resistance/Experimental Therapeutics/MetabolismModerators: Balveen Kaur, Ganesh Rao


7:30pm Multi-center study demonstrates radiomic NIMG-02 texture features derived from MR perfusion images predict pseudoprogression from true progression in glioblastoma patients Elshafeey N, Kotrotsou A, Abrol S, Hassan I, Hassan A, Agarwal A, Salek K, Bergamaschi S, Moron F, Law M, Zinn P, Colen R

7:34pm Standardized molecular analysis of primary PATH-40 central nervous system (CNS) tumors in a research based clinical practice. An introduction to the primary CNS tumor next generation sequencing (NGS) panel Siegel C, Armstrong T, Chung H, Crandon S, Patel S, Powers A, Quezado M, Ray-Chaudhury A, Vera E, Wu J, Xi L, Raffeld M, Gilbert M

7:38pm Radiologic phenotypes are treatment specific NIMG-51 and associated with survival - exploratory analysis of EORTC 26101 Nowosielski M, Gorlia T, Harting I, Radbruch A, Brandes A, Taphoorn M, Taal W, Domont J, Idbaih A, Campone M, Clement P, Stupp R, Fabbro M, Le Rhun E, von Deimling A, Platten M, Golfinopoulos V, Bendszus M, van den Bent M, Wick W

7:42pm A safety study of vemurafenib, an oral PDCT-19 inhibitor of BRAFV600E, in children with recurrent/refractory BRAFV600E mutant brain tumors: PNOC-002 Nicolaides T, Nazemi K, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Molinaro A, Mueller S, Prados M

7:46pm Volumetric 3D MR fingerprinting of adult NIMG-15 brain tumors: initial results Badve C, Kilinc O, Dastmalchian S, Ma D, Frankel S, O’Connor G, Sunshine J, Couce M, Griswold M, Gulani V, Barnholtz-Sloan J, Sloan A

7:50pm Computer based neurocognitive assessment PDCT-11 in children with central nervous system tumors treated with proton beam radiotherapy Contreras J, Stowe H, Dewees T, King A, Heimos H, Mccommis L, Perkins S

7:54pm Texture analysis of MR fingerprinting in adult NIMG-90 brain tumors Badve C, Dastmalchian S, Kilinc O, McGivney D, Ma D, Griswold M, Sunshine J, Gulani V, Barnholtz- Sloan J, Sloan A

7:58pm Detection of TERT mutations in a cell-free PATH-42 circulating tumor DNA (ctDNA) of glioblastoma patients using droplet digital PCR Cordova C, Corless B, Syeda M, Patel A, Delara M, Eisele S, Schafrick J, Placantonakis D, Pacione D, Silvverman J, Fatterpekar G, Shepherd T, Jain R, Snuderl M, Zagzag D, Golfinos J, Jafar J, Shao Y, Karlin-Neumann G, Polsky D, Chi A

8:02pm Volumetric analysis of IDH-mutant low-NIMG-50 grade glioma: A natural history study of tumor growth rates before and after treatment Huang R, Young R, Ellingson B, Veeraraghavan H, Wang W, Luks T, Kim J, Gerstner E, Schiff D, Peters K, Mellinghoff I, Chang S, Cloughesy T, Wen P

8:06pm Primary central nervous system lymphoma in RARE-05 immunocompromised hosts – a single institution retrospective study (2002-2017) Kaulen L, Galluzzo D, Hui P, Huttner A, Fulbright R, Baehring J

8:10pm Investigation of N-acetylcysteine for the NTOX-04 prevention of cisplatin chemotherapy-related cognitive impairments Lomeli N, Di K, Czerniawski J, Guzowski J, Bota D

8:14pm Prognostic factors and outcomes of patients CMET-08 with central nervous system (CNS) metastatic ALK-rearranged non-small cell lung cancer (NSCLC) Kachur E, Reiss S, Land J, Buie L, Reiner A, Panageas K, Riely G, Pentsova E

8:18pm Survival outcomes in pediatric recurrent high-PDCT-17 grade glioma: results of a 20-year systematic and meta-analysis Kline-Nunnally C, Felton E, Allen E, Tahir P, Mueller S

8:22pm Hispanic ethnicity and socioeconomic status EPID-14 are independently associated with improved prognosis in glioblastoma patients Ivan M, Richardson A, Moore K, Omuro A, De La Fuente M, Koru-Sengul T

8:26pm HER2 and triple negative breast cancer CMET-44 patients demonstrate an earlier time to development of brain metastases Cao T, Santa-Maria C, Kumthekar P




Imaging/Pediatrics/Outcomes/Practical and Applied Neuro-Oncology/PathologyModerators: Jason Huse, Cynthia Wetmore

M A I N M E E T I N G P R O G R A MSaturday, November 18, 2017




6:45-9:00am LIGHT CONTINENTAL BREAKFAST Yerba Buena Foyer & Golden Gate Foyer


Novel Metabolic Targets and Their Genetic Basis in GliomaDaniel Cahill (Chair)Yerba Buena Salon 9

• Metabolic profiling of gliomaSabrina Ronen

• Temozolomide and metabolism in IDH1 mutant gliomaDaniel Cahill

• Lipogenesis and glioblastomaDeliang Guo

• Metabolic dependencies induced by IDH1 mutationSamuel McBrayer

EANO/SNO: Glioblastoma in the Elderly: Solid Conclusions Built on Shifting Sand?Wolfgang Wick, Tracy Batchelor (Co-Chairs)Yerba Buena Salons 4-6

• Specific requirements of elderly patientsRoberta Rudá

• Update on molecular biomarkers in the elderlyJason Huse

• Surgery in the elderly glioma patientColin Watts

• Standard of care postsurgical therapy 2017James Perry

Using Patient Reports as a Measure of Net Clinical BenefitChristina Amidei (Chair)Yerba Buena Salons 10-12

• Innovative patient report measures in researchMartin Taphoorn

• Understanding the natural history of rare CNS tumors through patient self-report and web-based portalsTerri Armstrong

• Applying patient report measures as quality metrics in pediatric brain tumor careJin-Shei Lai

• Integrating patient report measures into neuro-oncology clinical practice: Opportunities for targeted interventionsChristina Amidei

Histone Mutations in Pediatric GliomasCynthia Hawkins (Chair)Yerba Buena Salon 8

• Oncohistones: Professional hijackers of the epigenomeNada Jabado

• The ABCs of chromatin biology and biochemical insights into the mechanisms of histone mutationsPeter Lewis

• Diagnostic and prognostic implications of histone mutations in clinical practiceCynthia Hawkins

• Targeting histone mutations in the clinic, are we there yet?Oren Becher

Brain MetastasesAdrienne Boire (Chair)Yerba Buena Salon 7

• Microenvironmental interactions in brain metastasisAdrienne Boire

• Brain metastasis genomicsPriscilla Brastianos

• Targeted therapy in brain metastasisManmeet Ahluwalia

• Brain metastasis-microenvironment interactions: an emerging source of innovative therapiesManuel Valiente

Joint AAN/SNO Session: Tumor Related EpilepsyJeffrey Politsky (Chair)Yerba Buena Salons 1-3

• EEG monitoring and brain mapping in TREJeffrey Politsky

• Epidemiology and etiology of TREJoon Uhm

• Medical/pharmacologic considerations in TREPatrick Wen

• Surgical management of tumor-related epilepsySandeep Mittal

6:00-7:00am MORNING YOGA Foothill C soc-neuro-onc.org/SNO/SNOCares soc-neuro-onc.org/SNO/SNOCares


12:15-1:15pm LUNCH Yerba Buena Foyer & Golden Gate Foyer

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONSNot sponsored by The University of Texas MD Anderson Cancer Center

Introduction to CRISPR-based Technologies Yerba Buena Salons 1-3Daniel Lim (Chair)• CRISPRi and CRISPRa for programmable transcriptional control, Daniel Lim• Opportunities and challenges of CRISPR-Cas gene editing, Jennifer Doudna• CRISPR/Cas9 for genome editing, Alexander Marson

Basic Science in Neuro-oncology for the Clinician Yerba Buena Salons 10-12Vinay Puduvalli (Chair)• Biology of primary brain tumors – the basics, Vinay Puduvalli• Basic immunology for the clinician, Amy Heimberger• Genomics and epigenomics in neuro-oncology: making sense of the maze, Russell Pieper

Quantitative Biology in Neuro-oncology Yerba Buena Salons 4-6Antonio Iavarone (Chair)• Public portal pearls and pitfalls; a hitchhiker’s guide to available data and analysis resources, Cameron Brennan• Large scale systems biology in brain cancer genomics, Michele Ceccarelli• Functional characterization of glioma cancer genes, Antonio Iavarone

Young Investigators Lunch - Demystifying the Grant Application Process Foothill G• Pre-grant preparation, Balveen Kaur• Writing the grant, Eva Galanis• Addressing an unfunded grant, Justin Lathia• The NIH perspective, Jane Fountain


9:00-12:00pm SATURDAY PLENARY SESSION Yerba Buena Salons 7-9

9:00-9:05am Welcome and Introduction Manish Aghi, Frank Furnari, Vinay Puduvalli

9:05-9:35am Keynote Presentation: New cancer technologies Jennifer Doudna

9:35-10:05am Keynote Presentation: MicroRNA dysregulation to identify therapeutic targets Carlo Croce

10:05-10:35am Victor Levin Award Introduction: Victor Levin

Victor Levin Lecture - Award Recipient: Susan Chang

10:35-10:50am BREAK Yerba Buena Foyer & Golden Gate Foyer

10:50-11:20am Presidential Address: E. Antonio Chiocca

11:20-11:25am Lifetime Achievement Award Recipient: Webster Cavenee

11:25-11:30am Platinum Supporter Awards

11:30-12:00pm LATE BREAKING ABSTRACTS11:30-11:45am First Results of the randomized phase II study on depatux –m alone, depatux-m in combination with LTBK-04 temozolomide and either temozolomide or lomustine in recurrent EGFR amplified glioblastoma: first report from INTELLANCE 2/EORTC trial 1410 van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J, Brandes A, Clement P, French P, Dubbink H, Kros J, Weller M, Chinot O, de Vos F, Whenham N, Sanghera P, Looman J, Lee H, de Geus J, Nuyens S, Spruyt M, Brilhante J, Gorlia T, Golfinopoulos V

11:45-12:00pm Multicenter randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly-diagnosed LTBK-03 glioblastomas Muragaki Y, Maruyama T, Ishikawa E, Nitta M, Ikuta S, Tsuboi K, Matsumura A, Nakamura H, Abe T, Saito R, Tabei Y, Arakawa Y, Momii Y, Karasawa K, Matsutani M, Ohno T, Nakazato Y, Maebayashi K




12:15-1:15pm LUNCH, continued

SNO International Outreach Luncheon Foothill F• Recap, Wilkins-Barrick Course in Neuro-Oncology, Sri Lanka, Ruvini Abeygunaratne• Recap, Wilkins-Barrick Course in Neuro-Oncology, Morocco, Mehdi Karkouri• Challenges that affect the delivery of care in Sub-Saharan Africa, Patricia Okiro

Surgical Trials: From Design to Regulatory Approval Nob Hill ABConstantinos Hadjipanayis (Chair)• Clinical trial design for neurosurgeons, Michael Vogelbaum• Getting FDA approval for devices and diagnostic tools (5-ALA), Constantinos Hadjipanayis• Phase 0 clinical trials and associated opportunities for neurosurgeons, Nader Sanai

Industry Supported SymposiaNot sponsored by The University of Texas MD Anderson Cancer Center• EGFR-targeted therapy for leptomeningeal carcinomatosis in non-small lung cancer Nob Hill CD• Targeting EGFR in glioblastoma: where we’ve been and where we’re going Yerba Buena Salons 13-15


CONCURRENT SESSION 5AMetabolomics/Cell Biology/Cell SignalingModerators: Zhimin Lu, Daniel CahillYerba Buena Salon 9

1:30-1:40pm Hypoxia inducible factor 1α reprograms METB-11 choline and ethanolamine phospholipid metabolism in mutant IDH1 gliomas Viswanath P, Phillips J, Pieper R, Ronen S

1:40-1:50pm Identification of a sexual dimorphism in METB-05 glioma pyruvate metabolism Wang Z, Rubin J, Ippolito J

1:50-1:55pm Targeting metabolic adaptation in MYC PDTM-46 driven pediatric neuronal tumors Delaidelli A, Negri G, Jan A, Jansonius B, Lim J, Leprivier G, Kool M, Pfister S, Remke M, Taylor M, Maris J, Sorensen P

1:55-2:00pm EGFR and EGFRvIII upregulate macrophage TMIC-51 infiltration in glioblastoma through TLR2 An Z, Weiss W

2:00-2:05pm Hyperpolarized [1-13C] pyruvate as a EXTH-71 biomarker for treatment monitoring in lymphoma murine models Tiret B, Autry A, Park I, Lu M, Anjum R, Drew L, Degorce S, Mayo M, Dillman K, Rubenstein J, Chaumeil M

2:05-2:15pm Reversal of glioblastoma replicative CSIG-38 immortality in a TERT promoter mutation- dependent manner Mancini A, Xavier-Magalhaes A, Woods W, Nguyen K, Amen A, McKinney A, Hayes J, Song J, Costa B, Perez-Pinera P, Costello J

2:15-2:25pm Clonal dynamics of human glioblastoma in TMOD-06 response to chemoradiotherapy Qazi M, Nixon A, Bakhshinyan D, Venugopal C, Vora P, Brown K, Subapanditha M, Yelle N, Chokshi C, Seyfrid M, Moffat J, Singh S

2:25-2:35pm Directed neuronal differentiation in GBM by CBIO-08 suppression of TAZ Audia A, Das A, Mukheef F, Zhang Z, Sulman E, Bhat K

2:35-2:45pm CIC protein instability drives cancer CSIG-23 phenotypes in glioblastoma Bunda S, Heir P, Metcalf J, Pusch S, Zadeh G, Aldape K

2:45-2:50pm ACOT7 regulates colonization of breast CBIO-29 cancer cells in the brain by regulating endoplasmic reticulum stress response Kanojia D, Panek W, Cordero A, Xiao A, Miska J, Wu M, Kim J, Zhou W, Ahmed A, Lesniak M

2:50-2:55pm Regulation of glioblastoma bioenergetics by CSIG-25 AMP kinase Dasgupta B, Chhipa R

2:55-3:00pm Induction of autophagy following TTFields CBIO-16 application serves as a survival mechanism mediated by AMPK activation Shteingauz A, Porat Y, Giladi M, Schneiderman R, Voloshin T, Munster M, Kirson E, Weinberg U, Palti Y

3:00-3:05pm Patient-derived glioblastoma cells release CBIO-22 ciliary vesicles that stimulate tumor cell proliferation Hoang-Minh L, Breunig J, Sarkisian M

3:05-3:10pm Pre-clinical study and clinical development of CSIG-31 AXL-targeting therapy for recurrent glioblastoma Sadahiro H, Kang K, Nabors B, Norian L, Hambardzumyan D, Dasgupta B, Nakada M, Nakano I





CONCURRENT SESSION 5BPractical and Applied Neuro-Oncology IModerators: Terri Armstrong, Martin TaphoornYerba Buena Salon 8

1:30-1:35pm Introduction Susan Chang

1:35-1:50pm Neurocognitive functioning in EORTC Brain NCOG-08 Tumor Group randomized phase II TAVAREC trial (EORTC 26091, NCT01164189) on temozolomide with or without bevacizumab in 1p/19q intact recurrent grade II & III gliomas Klein M, Reijneveld J, Idbaih A, Taal W, Clement P, de Vos F, Wick A, Mulholland P, Taphoorn M, Lewis J, Weller M, Verschuere T, Golfinopoulos V, Gorlia T, van den Bent M

1:50-2:05pm Cognitive functions and variants in genes NCOG-11 associated with aging and inflammation in brain tumor patients Correa D, Satagopan J, Onyewadume L, Kryza-Lacombe M, Leong S, Dimitriadoy S, O’Connell K, DeAngelis L, Orlow I Supported by the Sontag Foundation

2:05-2:15pm Memory functioning in low-grade glioma NCOG-07 patients treated with either radiotherapy (RT) or temozolomide (TMZ) chemotherapy. A correlative analysis of European Organization for Research and Treatment (EORTC) study 22033-26033 Klein M, Drijver J, van den Bent M, Hoang-Xuan K, Taphoorn M, Reijneveld J, Hassel M, Eekers D, Tzuk T, Lucas A, Golfinopoulos V, Gorlia T, Stupp R, Baumert B

2:15-2:25pm The added value of Health-Related Quality QLIF-27 of Life (HRQoL) as a prognostic indicator of overall survival and progression free survival in glioma patients: a meta-analysis based on individual patient data from randomized controlled trials Coomans M, Dirven L, Aaronson N, Baumert B, van den Bent M, Bottomley A, Brandes A, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Wick W, Reijneveld J, Taphoorn M

2:25-2:35pm Risk of glioma among people with asthma: EPID-19 a population-based case-control study using different control groups Lachance D, Kaur H, Ryan C, Sheen Y, Seol H, Wi C, King K, Ryu E, Juhn Y

2:35-2:45pm Neurocognitive outcomes of EORTC Brain NCOG-19 Tumor Group study 26101 phase III trial comparing the combination of lomustine and bevacizumab with lomustine alone in glioblastoma patients with first progression Klein M, Reijneveld J, Idbaih A, Brandes A, Taal W, Clement P, Domont J, Campone M, Taphoorn M, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, Golfinopoulos V, Platten M, Gorlia T, van den Bent M, Wick W

2:45-2:55pm Health related quality of life and QLIF-47 neurological deterioration free survival in INTELLANCE 2/EORTC trial 1410, a randomized phase II study on ABT414 in recurrent EGFR amplified glioblastoma Clement P, van den Bent M, Eoli M, Sepulveda J, Walenkamp A, Frenel J, Franceschi E, Weller M, Chinot O, de Vos F, Whenham N, Sanghera P, Looman J, Lee H, de Geus J, Nuyens S, Spruyt M, Gorlia T, Coens C, Golfinopoulos V

2:55-3:05pm Burnout among neuro-oncology professionalsQLIF-39 Yust-Katz S, O’Brien B, Acquaye A, Vera E, Armstrong T

3:05-3:15pm Risk factors for burnout among neuro-QLIF-30 oncology providers: a predictive model O’Brien B, Yust-Katz S, Vera E, Acquaye A, Armstrong T


CONCURRENT SESSION 5CImagingModerators: Sabrina Ronen, Joerg-Christian TonnYerba Buena Salon 7

1:30-1:40pm Photopenic defects on O-(2-18F-fluoroethyl)-NIMG-47 L-tyrosine PET - clinical relevance in glioma patients Galldiks N, Unterrainer M, Judov N, Stoffels G, Lohmann P, Vettermann F, Dunkl V, Suchorska B, Tonn J, Kreth F, Fink G, Bartenstein P, Langen K, Albert N

1:40-1:50pm Experience with 18F-FET PET/MRI for CNS-NIMG-42 tumors in children and adolescents Marner L, Nysom K, Sehested A, Borgwardt L, Mathiasen R, Wehner P, Henriksen O, Lundemann M, Thomsen C, Bøgeskov L, Skjøth-Rasmussen J, Broholm H, Scheie D, Juhler M, Højgaard L, Law I

1:50-1:55PM Usefulness of 18FET-PET for chemotherapy NIMG-100 monitoring in non-contrast enhancing glioma Suchorska B, Unterrainer M, Biczok A, Albert N, Tonn J, Kreth F

1:55-2:00pm Patterns of intersectional tumour volume NIMG-39 in T2-weighted MRI and 18F-FET PET correlate with outcome in glioblastoma Suchorska B, Sosnova M, Unterrainer M, Biczok A, Bartenstein P, Albert N, Tonn J

2:00-2:10pm Radiomic analysis of pseudo-progression NIMG-91 compared to true progression in glioblastoma patients: A large-scale multi- institutional study Abrol S, Kotrotsou A, Hassan A, Elshafeey N, Agarwal A, Hassan I, Idris T, Salek K, Farid N, McDonald C, Weathers S, Bahrami N, Bergamaschi S, Elakkad A, Alfaro-Munoz K, Moron F, Huse J, Weinberg J, Heimberger A, Sawaya R, Kumar A, de Groot J, Law M, Zinn P, Colen R

APPLIED NEURO-ONCOLOGY AWARD

APPLIED NEURO-ONCOLOGY AWARD





2:10-2:20pm Rapid accurate intraoperative diagnosis of NIMG-22 pediatric brain tumors using stimulated Raman histology Hollon T, Lewis S, Pandian B, Niknafs Y, Garton H, Maher C, Muraszko K, Camelo-Piragua S, Orringer D

2:20-2:30pm Impact of post-surgical enhancing tumor NIMG-77 volume and T2/FLAIR volume on the survival impact of bevacizumab in NRG Oncology/ RTOG 0825 Vogelbaum M, Swanson K, Zhang P, Cahill D, Hawkins-Daarud A, Gilbert M, De Leon G, Rickertsen C, Kunkel L, Shi W, Penas-Prado M, Youssef E, Shu H, Wendland M, Suh J, Keech J, Howard S, Kaluza V, Won M, Mehta M

2:30-2:40pm Resting state functional MRI shows NIMG-95 disturbances in functional connectivity in the non-lesional hemisphere in patients with high-grade glioma Stöcklein V, Stoecklein S, Ertl-Wagner B, Thon N, Kreth F, Tonn J, Liu H

2:40-2:50pm Deep learning approaches to identify intra-NIMG-89 tumoral heterogeneity of low and high grade gliomas Chang P, Bota D, Filippi C, Chow D

2:50-2:55pm P53 amplification modifies the glioblastoma NIMG-99 microenvironment: Differentiating the contribution of cells vs edema in the T2 weighted MRI signal Jackson P, Gaw N, Hawkins-Daarud A, DeGirolamo L, Baxter L, Smith K, Nakaji P, McGee S, Clark- Swanson K, Bendok B, Wu T, Hu L, Li J, Swanson K

2:55-3:00pm Shape attributes of enhancing lesion NIMG-80 boundaries can differentiate tumor recurrence from pseudo-progression on routine brain MRI scans: Preliminary findings Isamail M, Prasanna P, Huang R, Singh G, Thawani R, Madabhushi A, Ahluwalia M, Tiwari P

3:00-3:05pm Deep learning for survival predicting in IDH NIMG-96 wild-type gliomas Chang P, Chow D, Bota D, Poisson L, Filippi C, Jain R

3:05-3:10pm Increased mutation burden (hypermutation) NIMG-28 in gliomas is associated with a unique radiomic texture signature in magnetic resonance imaging Hassan I, Kotrotsou A, Kamiya Matsuoka C, Alfaro-Munoz K, Elshafeey N, Zinn P, de Groot J, Colen R



CONCURRENT SESSION 6ACNS MetastasesModerators: Manmeet Ahluwalia, Priscilla BrastianosYerba Buena Salon 9Supported by the American Brain Tumor Association

3:30-3:40pm Introduction Paul Brown

3:40-3:55pm High aldehyde dehydrogenase activity TMIC-07 identifies brain metastasis-initiating cells in breast cancer Minata M, Alsheikh H, Harada S, Peker D, Gillespie Y, Cerione R, Tannous B, Nakano I, Samant R, Lu S, Yamaguchi S

3:55-4:05pm Identification of a novel tyrosine kinase/ ANGI-12 integrin complex that drives brain metastases Jahangiri A, Sidorov M, Nguyen A, Yagnik G, Han S, Mascharak S, De Lay M, Wagner J, Castro B, Imber B, Lu K, Bergers G, Weiss W, Aghi M

4:05-4:15pm PIK3 mutations are associated with RTHP-33 decreased local control in brain metastases treated with radiation Lockney N, Wang D, Lin A, Pei X, Chan T, Yamada Y, Beal K, Yang T

4:15-4:25pm Pan-cancer profiles of brain metastases: CMET-09 prioritization of therapeutic targets Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos P, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, Ibrahim N, de Groot J, McCarty J, O’Brien B, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A

4:25-4:30pm Detection, molecular profiling and culture of CMET-36 CSF-CTCs in leptomeningeal disease (LMDz) in melanoma Evernden B, Law V, Kenchappa R, Puskas J, Ryzhova E, Fedorenko I, Tran N, Etame A, Sahebjam S, Magliocco A, Smalley K, Forsyth P

4:30-4:35pm T lymphocytes facilitate brain metastasis of IMMU-56 breast cancer by expressional imprinting Pedrosa R, Valiente M, Luider T, Debets R, Kros J, Mustafa D

4:35-4:40pm N107C/CEC.3 (Alliance for Clinical Trials NCOG-06 in Oncology/Canadian Cancer Trials Group): Phase III Trial of post-operative radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease: cognitive function of long-term survivors Roberge D, Ballman K, Cerhan J, Anderson S, Carrero X, Whitton A, Greenspoon J, Parney I, Laack N, Ashman J, Bahary J, Hadjipanayis C, Urbanic J, Barker F, Farace E, Khuntia D, Garces Y, Giannini C, Buckner J, Galanis E, Brown P



4:40-4:45pm Pretreatment volume of MRI-determined NCOG-02 white matter injury (WMI) predicts cognitive decline after hippocampal avoidant (HA) WBRT for brain metastases: Secondary analysis of NRG Oncology RTOG 0933 Bovi J, Pugh S, Sabsevitz D, Robinson C, Paulson E, Mehta M, Gondi V, Kundapur V, Pinover W, Chao S, Machtay M, DeNittis A, Laack N, Greenspoon J, Mannel R, Huang J, Dominello M, Kachnic L

4:45-4:50pm Impact of tumor size and molecular profile CMET-11 on local control in patients with breast cancer brain metastases: understanding tumor biology and radiosurgery dosing Kotecha R, Miller J, Mohammadi A, Murphy E, Suh J, Barnett G, Vogelbaum M, Angelov L, Ahluwalia M, Chao S

4:50-4:55pm Overall survival of melanoma brain CMET-41 metastasis patient cohorts treated with stereotactic radiosurgery with or without immunotherapy Nguyen S, Pearson L, Keller A, All S, Patel H, Ramakrishna N


CONCURRENT SESSION 6BPractical and Applied Neuro-Oncology IIModerators: Zarnie Lwin, Jeffrey WefelYerba Buena Salon 8

3:30-3:40pm Illness communication, spousal support and QLIF-10 symptom burden in couples coping with Glioma Milbury K, Lopez G, Weathers S, Eto O, Li J, Cohen L

3:40-3:50pm Genetic markers and clinical characteristics NCOG-20 related to neurocognitive outcomes of pediatric brain tumor patients Kline-Nunnally C, Felton E, Edwards C, Fullerton H, Torkildson J, Gauvain K, Samuel D, Mueller S

3:50-4:00pm Health-related quality of life results from QLIF-12 the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact firs recurrence WHO grade II and III glioma (EORTC 26091) Reijneveld J, Coens C, Taphoorn M, Sillevis Smitt P, Clement P, Idbaih A, de Vos F, Klein M, Wick W, Mulholland P, Lewis J, Golfinopoulos V, Bottomley A, van den Bent M

4:00-4:05pm Hospice use among patients with high grade PALL-08 gliomas Forst D, Adams E, Nipp R, Martin A, Aizer A, Jordan J

4:05-4:10pm A pilot study of cognitive functions, APOE NCOG-16 and amyloid imaging in glioma patients Correa D, Kryza-Lacombe M, Zhou X, Baser R, Beattie B, Beiene Z, Humm J, DeAngelis L, Orlow I, Weber W, Osborne J

4:10-4:15pm Psychological distress and prognostic PALL-09 understanding in patients with malignant gliomas and their caregivers Forst D, Quain K, Poisson K, Eusebio J, Jackson V, Greer J, El-Jawahri A, Temel J

4:15-4:20pm Effects of integrative therapies on distress, QLIF-35 pain, and fatigue in patients with primary brain tumors: preliminary results from an integrative medicine registry Donovan L, Rusilowski A, Taromina K, Kreisl T, Welch M, Lassman A, Ladas E, Iwamoto F

4:20-4:25pm I-CoPE: A pilot study of an innovative model PALL-03 of supportive and palliative care for patients with high grade glioma and their family carers Philip J, Collins A

4:25-4:30pm Seizure control after initial presentation in NCMP-01 IDH mutated glioma patients Ozer B, Bui Y, Markovic D, Nguyen H, Liau L, Nghiemphu P, Cloughesy T, Lai A

4:30-4:35pm Design and implementation of a survivorship QLIF-06 programme in an unselected cohort of newly diagnosed brain tumour patients: feasibility and application of routine holistic needs assessment McBain C, Emerson J, Molloy E, Robson S, Cundliffe S, Gilston-Hope A, Smith C, Wadeson A

4:35-4:40pm Postoperative delirium in glioblastoma NTOX-10 patients: Risk factors and prognostic implications Flanigan P, Jahangiri A, Weinstein D, Kanungo I, Choi S, Dayani F, Molinaro A, McDermott M, Berger M, Aghi M

4:40-4:45pm Improved survival of glioblastoma patients HOUT-12 treated at academic cancer programs: A Hospital-based Study from the National Cancer Database Zhu P, Du X, Zhu J, Esquenazi Y

4:45-4:50pm Neuro-oncology burnout: impact of QLIF-02 professional stressors and job satisfaction Acquaye A, Vera E, Yust-Katz S, O’Brien B, Armstrong T





CONCURRENT SESSION 6CRANO UpdateModerators: Susan Chang, David MacDonald, Martin van den Bent, Michael Vogelbaum, Patrick WenYerba Buena Salon 7

3:30-3:35pm Introduction Patrick Wen

3:35-3:50pm Brain metastases clinical trial design and endpoints Eudocia Quant Lee, Brian Alexander

3:50-3:55pm Leptomeningeal disease Riccardo Soffietti, Manmeet Ahluwalia

3:55-4:05pm PET Joerg-Christian Tonn

4:05-4:11pm Meningioma Patrick Wen, Ray Huang, Michael Vogelbaum

4:11-4:18pm NANO Lakshmi Nayak, David Reardon

4:18-4:28pm Seizures-the next step: redesign outcome measures Edward Avila

4:28-4:38pm Patient reported outcomes Martin Taphoorn, Terri Armstrong

4:38-4:45pm Steroids Patrick Wen, Nils Arvold

4:45-4:55pm Proposal for a “modified RANO” criteria for treatment-agnostic response evaluation in HGG Benjamin Ellingson

4:55-5:03pm Novel endpoints for low grade gliomas Raymond Huang

5:03-5:11pm Challenges in assessing response to therapy in recurrent patients in the postoperative setting Peter Canoll

5:11-5:21pm Phase 0 trials in Neuro-Oncology Michael Vogelbaum

5:21-5:30pm Next steps Patrick Wen

5:00-7:00pm POSTER SESSION Traditional Poster Viewing Golden Gate AB

5:00-7:00pm EVENING SURVIVORSHIP SESSION Identifying Needs and Developing Interventions Nob Hill Nursing & Allied Health Professional Networking Session supported by Novocure

7:00-11:00pm SNO GALA Held at AT&T Park, home of the San Francisco Giants baseball team. Buses depart from Mission Street. (Separate Ticket Required)

5:00-7:00pm E-TALKS Interactive Electronic 4 Minute Presentations Followed By Group Discussions - Golden Gate C1/C2/C3 Group 1: Adult Therapeutics Golden Gate C1 Group 2: Angiogenesis/Invasion/Microenvironment/Immunology Golden Gate C2 Group 3: Pediatric Basic Science/Stem Cells Golden Gate C3




Adult TherapeuticsModerators: Jian Campian, Michelle Kim

5:28pm Phase I trial of anti-LAG-3 or anti-CD137 ATIM-23 alone and in combination with anti-PD-1 in patients with recurrent GBM Lim M, Ye X, Nabors B, Piotrowski, MD A, Fisher J, Desideri S, Sims M, Wen P, Grossman S

5:32pm A Phase 1 study of Ad-RTS-hIL-12 + ATIM-26 veledimex in adult recurrent glioblastoma Chiocca E, Yu J, Lukas R, Buck J, Demars N, Barrett J, Yang Y, Cooper L, Lebel F

5:36pm Recommended phase II dose of intra-arterial NTOX-09 melphalan given with intra-arterial carboplatin, osmotic blood-brain barrier disruption and delayed otoprotective sodium thiosulfate for patients with recurrent or progressive CNS embryonal or germ cell tumors Ambady P, Doolittle N, Firkins J, Prola Netto J, Siler D, James J, Johansson K, Huddleston A, Fu R, Neuwelt E

5:40pm Post-surgical, residual enhancing tumor NIMG-53 volume is prognostic for overall survival in newly diagnosed glioblastoma: Evidence from 1,458 patients pooled from international trials, single institution databases, and multicenter consortiums Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, de Groot J, Chang S, Mellinghoff I, Young R, Colen R, Taylor J, Arrillaga-Romany I, Huang R, Pope W, Reardon D, Batchelor T, Wen P, Prados M, Cloughesy T

5:44pm Radiation therapy patterns of care for CMET-13 non-small cell lung cancer brain metastases: an analysis of the National Cancer Database Dulaney C, Fiveash J, Li P, Boggs H

5:48pm Survival benefit associated with adjuvant MNGI-10 radiotherapy in elderly patients with WHO grade III meningioma Zhou H, Huang R, Karakousis G, Zhang P, Chan L, Bai H, Xiao B, Yang L

5:52pm The effect of immunotherapy treatment CMET-32 on local control for melanoma brain metastases treated with stereotactic radiosurgery Pearson L, Nguyen S, Keller A, All S, Patel H, Ramakrishna N

5:56pm Efficacy and toxicity of stereotactic CMET-24 radiosurgery for treatment of patients with 10 or more brain metastases Braunstein S, Garcia M, Scharfen J, Ma L, Nakamura J, Fogh S, Aghi M, Theodosopoulos P, McDermott M, Sneed P


5:00pm A phase Ib/II, open-label, multicenter study of ACTR-74 capmatinib (INC280) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma van den Bent M, Azaro A, Vos F, Sepulveda J, Yung W, Wen P, Lassman A, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Vicente S, Myers A, Wick W

5:04pm Biomarker analysis supports the VB-111 dual ATIM-03 mechanism of action Gruslova A, Liu Y, Wen P, Peters KB, Vredenburah J, Bokstein F, Blumenthal DT, Cohen Y, Mendel I, Breitbart E, Brenner A

5:08pm A phase I study of neural stem cells loaded ACTR-36 with an oncolytic adenovirus for patients with newly diagnosed malignant glioma: Preliminary safety and data analysis Lesniak M, Stupp R, Sachev S, Lukas R, Chandler J, Portnow J, Amidei C, Miska J, Balyasnikova I, Ahmed A, Curiel D, Strong T, LeFever A, Adams A, Giles F, Aboody K

5:12pm Phase I trial of TG02 plus dose-dense or ACTR-69 metronomic temozolomide for adults with recurrent anaplastic astrocytoma and glioblastoma Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park D, Parrott T, Armstrong T, Yuan Y, Gilbert M

5:16pm Comparison of local control of brain CMET-43 metastases with stereotactic radiosurgery versus surgical resection: A secondary analysis of EORTC 22952-26001 Churilla T, Chowdhury I, Handorf E, Collette L, Collette S, Dong Y, Alexander B, Kocher M, Soffietti R, Claus E, Weiss S

5:20pm Final analysis of phase II combining MNGI-13 everolimus and octreotide for patients with refractory and documented progressive meningioma (CEVOREM) Graillon T, Sanson M, Peyre M, Peyrière H, Autran D, Kalamarides M, Roche P, Fuentes S, Tabouret E, Barrie M, Campello C, Idbaih A, Boucekine M, Figarella-Branger D, Barlier A, Dufour H, Chinot O

5:24pm A 2-part safety and exploratory efficacy ACTR-56 randomised double-blind, placebo- controlled study of a 1:1 ratio of cannabidiol and delta9tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM) Short S, Little C, The Cannabinoid in Recurrent Glioma Study Group



5:00pm Inhibition of APLN-APLNR signalling blocks ANGI-02 tumour angiogenesis and attenuates invasive glioblastoma growth Glass R, Mastrella G, Hou M, Stöcklein V, Miletic H, Herold-Mende C, Synowitz M, Vescovi A, Bjerkvig R, Schüller U, Tonn J, Kaelin R

5:04pm Accurate patient-specific machine learning NIMG-68 models of glioblastoma invasion using transfer learning Hu L, Yoon H, Eschbacher J, Baxter L, Smith K, Nakaji P, Mcgee S, Dueck A, Quarles C, Karis J, Hawkins-Daarud A, Jackson P, Massey S, Wu T, Swanson K, Li J

5:08pm Radiomics of tumor invasion 2.0: combining NIMG-74 mechanistic tumor invasion models with machine learning models to accurately predict tumor invasion in human glioblastoma patients Swanson K, Gaw N, Hawkins-Daarud A, Jackson P, Singleton K, DeGirolamo L, Eschbacher J, Baxter L, Smith K, Nakaji P, McGee S, Clark-Swanson K, Bendok B, Dueck A, Wu T, Li J, Hu L

5:12pm Regulation of the protease ADAM17 by TMIC-48 extracellular signals drives pro-tumoral programs in glioblastoma cells and their microenvironment Nandhu M, Bhaskaran V, Hu B, Viapiano M

5:16pm Quantifying interstitial fluid flow in TMIC-28 glioblastoma using dynamic contrast enhanced MRI Kingsmore K, Munson J

5:20pm Deciphering glioma intrinsic transcriptional TMIC-22 subtypes identifies tumor evolution associates with changes in immune- microenvironment Wang Q, Hu B, Hu X, Squatrito M, Scarpace L, deCarvalho A, Lyu S, Li P, Li Y, Barthel F, Cho H, Lin Y, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Olar A, Lan Z, Finocchiaro G, Phillips J, Berger M, Gabrusiewicz K, Wang G, Eskilsson E, Hu J, Mikkelsen T, Depinho R, Muller F, Heimberger A, Sulman E, Nam D, Verhaak R

5:24pm Inhibition of SLC7A11 reduces excitatory TMIC-20 synaptic input of peritumoral neurons in glioma patients Sauvigny T, Dührsen L, Kuhl D, Westphal M, Ohana O, Martens T

5:28pm A novel chimeric model to accurately IMMU-50 identify TAMMs in glioblastoma Youshani A, Yu K, Wilkinson F, O’Leary C, Cook P, Liao A, Pathmanaban O, Waugh C, Shorrock H, MacDonald A, Roncaroli F, Kamaly-Asl I, Bigger B

5:32pm Reducing the ex vivo manufacturing time IMMU-17 of EGFRvIII-specific chimeric antigen receptor (CAR) T cells improves phenotype and demonstrates potent anti-glioma function in vivo Tanaka R, Caruso H, Ling X, Najjar A, Heimberger A

5:36pm Overcoming glioblastoma resistance to IMMU-63 immune checkpoint blockade via RNA- loaded nanoparticles Sayour E, Grippin A, Mendez-Gomez H, De Leon G, Mitchell D

5:40pm Immunological activation in responding ATIM-25 patients with recurrent HGG after treatment with Toca 511 & Toca FC: Results from a phase 1 trial Ostertag D, Accomando W, Hogan D, Diago O, Gammon D, Haghighi A, Mitchell L, Rodriguez- Aquirre M, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Chen C, Vogelbaum M, Gruber H, Das A, Jolly D

5:44pm Tumor genetics and macrophage ontogeny TMIC-11 shape the innate immune response to glioma Mueller S, Kohanbash G, Liu S, Carrera D, Watchmaker P, Jahan N, Alvarado B, Lim D, Aghi M, Okada H, Diaz A

5:48pm CD317 expression in human glioblastoma: a IMMU-54 target for immunotherapy Gramatzki D, Szabo E, Gramatzki M, Peipp M, Weller M

5:52pm GCN2 kinase is essential for adaptive T-cell IMMU-06 immunity in glioma Rashidi A, Miska J, Pituch K, Kanojia D, Lopez- Rosas A, Han Y, Kim J, Panek W, Muroski M, Lesniak M

5:56pm A liquid biopsy to assess tumor recurrence: EXTH-63 presence of Mo-MDSC and CD14+ VNN2+ cells in peripheral blood as a biomarker to distinguish brain metastasis (BM) from radiation necrosis after stereotactic radiosurgery Soler D, Young A, Kerstetter-Fogle A, Barnholtz- Sloan J, Cooper K, McCormick T, Sloan A




Angiogenesis/Invasion/Microenvironment/ImmunologyModerators: Katrin Lamszus, Jing Wu


Pediatric Basic Science/Stem CellsModerators: Vivianne Tabar, Sameer Agnihotri

5:00pm Combined BET bromodomain and CDK2 PDTM-34 inhibition in MYC-driven medulloblastoma Bolin S, Borenvik A, Persson C, Sundstrom A, Qi J, Bradner J, Weiss W, Cho Y-J, Weishaupt H, Swartling F

5:04pm Systematic drug identifies Digoxin as a PDTM-07 drug that prolongs survival in PDOX models of groups 3 and 4 medulloblastoma at clinically relevant doses Injac S, Huang L, Zhao H, Qi L, Kogiso M, Man C, Li X-N, Lau, C, Wong S

5:08pm Radiation DNA damage repair inhibition by PDTM-44 GSK-J4 induced chromatin compaction in DIPG Louis N, He X, Piunti A, Morgan M, Unruh D, Saratsis A, Lulla R, Fangusaro J, Horbinski C, Goldman S, James C, Shilatifard A, Hashizume R

5:12pm Next-generation sequencing of diffuse PDTM-02 intrinsic pontine glioma cells reveals altered epigenetic regulation and distinct tumor subgroups Saratsis A, Huang T, Bartom E, Marshall S, Qi J, Hashizume R, James C, Shilatifard A

5:16pm Regulation of bioenergetics through dual METB-15 inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres Park J, Shim J, Kang J, Kim E, Chang J, Kim S, Kang S

5:20pm Functional genomic analysis of MYC-PDTM-36 amplified medulloblastoma nominates the TGFb pathway as a clinically viable target Henderson J, Cho H, Davare M, Tsherniak A, Cowley G, Weir B, Hahn W, Cho Y

5:24pm Single-cell mass cytometry of human STEM-22 glioblastoma reveals phenotypic heterogeneity and distinct cell cycle and epigenetic states among glioma stem cells Simonds E, Cayanan G, Park J, Bendall S, Nolan G, Weiss W

5:28pm Toca 511 & Toca FC: Pre-clinical proof of PDTM-19 concept in medulloblastoma Richardson A, Collins S, Inagaki A, Armstrong V, Roussel M, Jolly D, Robbins D, Ayad N, Kasahara N

5:32pm Modeling glioblastoma through cancer stem TMOD-16 cell organoids Hubert C, Rivera M, Wallace L, Wu Q, Mack S, Prager B, Miller T, Couce M, McLendon R, Sloan A, Rich J

5:36pm Human stem cell based model of TMOD-11 medulloblastoma Huang M, Tailor J, Zhen Q, Phillips J, Morrissy S, Kool M, Pfister S, Swartling F, Taylor M, Smith A, Weiss W

5:40pm Lamina organization promotes maintenance STEM-29 of brain tumor initiating cells in glioma Lai S, Prager B, Wang X, Rich J

5:44pm The TCF12 transcription factor controls STEM-19 proneural glioblastoma stem-like cells Taiwo R, Mao D, Mahlokozera T, Kim A

5:48pm DOT1L epigenetically regulates GBM brain STEM-28 tumor stem cells Bozek D, Wang A, Hao X, Johnston M, Luchman H, Weiss S

5:52pm High expression of LGR5 maintains CBIO-25 glioblastoma stem cells in a proneural state and promotes self-renewal and invasion Xie Y, Sundström A, Tan E, Marinescu V, Maturi N, Tirfing M, Blokzijl A, Jin C, Chen L, Essand M, Swartling F, Nelander S, Jiang Y, Uhrbom L

5:56pm A CD133-Akt-Wnt signaling axis provides CSIG-22 functional insight into the role of CD133 in glioblastoma brain tumor-initiating cells Manoranjan B, Venugopal C, Mahendram S, Subapanditha M, Savage N, Qazi M, Vora P, Moffat J, Doble B, Singh S





M A I N M E E T I N G P R O G R A MSunday, November 19, 2017

6:45-9:00am LIGHT CONTINENTAL BREAKFAST Yerba Buena Foyer


Circulating Biomarkers - Technology and ApplicationAgnieszka Bronisz (Chair)Yerba Buena Salon 9

• EVs - biomarkers and effectors of the oncogene-driven cellular interactome in cancerJanusz Rak

• Glioblastoma transgenic mouse models for advance in biomarker studiesAlain Charest

• Immune evasion mediated by PD-L1 on glioblastoma-derived exosomesSean Lawler

• Heterogeneity of EVs cargo in the progression and therapeutic response in glioblastomaAgnieszka Bronisz

Clonal Evolution of Adult and Pediatric GliomaJoseph Costello (Chair)Yerba Buena Salon 8

• Deciphering single-cell programs in adult and pediatric gliomasMario Suva

• Deconstructing clonal composition in glioma through multiomic analysis of serial sectionsMichael Oldham

• Clonal evolution and prediction of pharmacologic vulnerabilities of human gliomaAntonio Iavarone

• Integrated model of clonal evolutionJoseph Costello

Viral Therapy: Advances from Bench to BedsideJames Markert (Chair)Yerba Buena Salons 4-6

• Determining the optimal dose for phase II/III studies of OV: The lesson of poliovirusAnnick Desjardins

• Combination of oncolytic adenoviruses and positive regulators of the immune synapsisJuan Fueyo

• Toca 511 clinical trials and bedside-to-bench studies indicate implications of transcriptome profiling and immune monitoring for glioma virotherapyNoriyuki Kasahara

• Oncolytic HSV for glioma-potential for childhood cancers and use of immunogene therapyJames Markert

Discovery, Characterization and Functionalizing Novel Glioma GenesMelissa Bondy (Chair) Yerba Buena Salons 1-3

• Overview of glioma epidemiologic studiesMelissa Bondy

• Germline mutations in glioma families identified through whole genome sequencingMatthew Bainbridge

• Identification of novel SNPS identified through GWAS analysisMargaret Wrensch

• Developing functional pipelines to screen driver genes in mouse models of gliomaBenjamin Deneen

Meningiomas: Molecular Advances Toward Developing Targeted TherapiesGelareh Zadeh (Chair)Yerba Buena Salons 10-12

• Molecular testing in meningioma: beyond WHO gradeKenneth Aldape

• Lessons learned from genomic landscape of atypical meningiomasIan Dunn

• RNA pathway analysis directing therapeutic strategies in meningiomasGelareh Zadeh

• Challenges and opportunities in clinical trials for meningiomasMichael Jenkinson

Developing Cancer Stem Cell Targeting StrategiesJustin Lathia (Chair)Yerba Buena Salon 7

• Attenuating cell-cell communication in CSCs via drug repurposing strategiesJustin Lathia

• Metabolic targeting of slow-cycling cancer stem cells in glioblastomaLoic Deleyrolle

• Sexual dimorphism in CSC drug responsesJoshua Rubin

• Using pluripotent stem cells to model CSCs and identify novel drug targetsViviane Tabar




CONCURRENT SESSION 7APediatrics - ClinicalModerators: Annie Huang, Soumen KhatuaYerba Buena Salon 9

8:30-8:35am A phase I dose escalation trial of the MEK1/2 PDCT-24 inhibitor MEK162 (binimetinib) in children with low-grade gliomas and other Ras-Raf pathway-activated tumors: initial report Robison N, Pauly J, Malvar J, Filbin M, Loret de Mola R, Dorris K, Bendel A, Bowers D, Bornhorst M, Gauvain K, Leary S, MacDonald T, Gardner S, Reddy A, Diaz P, Tan Y, Sinai C, Davidson, MD T, Ullrich N, Margol A, Dhall G, Borchert M, Ligon K, Sposto R, Kieran M

8:35-8:50am Long-term impact of radiation dose and NCOG-15 volume on intellectual functioning (IQ) for children diagnosed with medulloblastoma: A report from the Children’s Oncology Group (COG) Embry L, Gioia A, Li Y, Han Y, Cullen P, Janss A, Michalski J, Billups C, Noll R, Hardy K

8:50-9:05am Neurocognitive outcome in children with s NCOG-12 ensorineural hearing loss following treatment for malignant embryonal brain tumors Moxon-Emre I, Dahl C, Ramaswamy V, Bartels U, Tabori U, Huang A, Cushing S, Papaioannou V, Laperriere N, Bouffet E, Mabbott D

9:05-9:20am Clinically integrated sequencing significantly PDCT-14 alters therapy in children and young adults with high-risk glial brain tumors Koschmann C, Wu Y, Kumar C, Lonigro R, Vats P, Kasaian K, Cieslik M, Cao X, Frank K, Prensner J, Zureick A, Everett J, Anderson B, Mullan B, Marini B, Camelo-Piragua S, Vennneti S, Mc Keever P, McFadden K, Lieberman A, Leonard M, Maher C, Garton H, Muraszko K, Robertson P, Robinson D, Chinnaiyan A, Mody R

9:20-9:30am Molecular diagnostics reveal 60% higher PDCT-05 survival for molecularly-verified versus histopathologically-diagnosed pediatric supratentorial central nervous system embryonal tumors and pineoblastomas; a report from the Children’s Oncology Group ACNS0332 trial Hwang E, Kool M, Burger P, Capper D, Chavez L, Brabetz S, Williams-Hughes C, Billups C, Heier L, Jaju A, Michalski J, Li Y, Zhou T, Leary S, Heideman N, von Deimling A, Jones D, Gajjar A, Packer R, Pfister S, Olson J

9:30-9:40am Temozolomide with irinotecan versus PDCT-09 temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma/CNS PNET of childhood: Report of a COG Randomized Phase II Screening Trial Levy A, Krailo M, Chi S, Williams-Hughes C, Bancroft M, Villaluna D, Fouladi M, Gajjar A

9:40-9:50am Safety and efficacy of intraventricular PDCT-04 131I-labeled monoclonal antibody 8H9 targeting the surface glycoprotein B7-H3 in patients with CNS/LM disease Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, Lewis J, Lyashchenko S, Larson S, Cheung N

9:50-9:55am Radio-immunotherapy using the IDO-PDCT-06 inhibitor indoximod in combination with re-irradiation for children with progressive brain tumors in the phase 1 setting: an updated report of safety and tolerability (NCT02502708) Johnson T, Aguilera D, Al-Basheer A, Cooksey R, Eaton B, Esiashvili N, Firat S, Fiveash J, Foreman N, Fridlyand D, Friedman G, Giller C, Grosshans D, Heger I, Kelly M, Kennedy E, Knipstein J, Kolhe R, Liu A, Martin W, Mourad W, Pacholczyk R, Parker R, Rojiani A, Sadek R, Thornton A, Vahanian N, MacDonald T, Munn D

9:55-10:00am Liquid biopsy for monitoring of tumor GENE-43 response in children with diffuse midline glioma Panditharatna E, Kambhampati M, Yadavilli S, Sandy J, Yang X, Kilburn L, Crawford J, Magge S, Packer R, Prados M, Mueller S, Nazarian J

10:00-10:05am The active regulatory landscape of PDTM-23 ependymal tumors Mack S, Pajtler K, Chavez L, Pfister S, Kool M, Taylor M, Rich J

10:05-10:10am Discussion


PEDIATRIC CLINICAL RESEARCH AWARD

PEDIATRIC CLINICAL RESEARCH AWARD



CONCURRENT SESSION 7BMolecular Pathology - Adult and PediatricModerators: Craig Horbinski, Sean LawlerYerba Buena Salon 8

8:30-8:35am Introduction Roel Verhaak

8:35-8:50am Global reduction in H3K27me3, similar to PDTM-49 H3K27M mutant gliomas, is a molecular surrogate for pediatric posterior fossa- group A ependymomas Venneti S, Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, Yip S, Hukin J, Sun Y, Schipper M, Chavez L, Margol A, Pekmezci M, Chung C, Banda A, Bayliss J, Curry S, Santi M, Rodriguez F, Snuderl M, Karajannis M, Saratsis A, Horbinski C, Kool M, Pfister S, Taylor M, Hawkins C, Korshunov A, Judkins A

8:50-9:05am Large scale tumor mutational burden PDTM-21 analysis of pediatric tumors provides a diagnostic tool for germline predisposition and reveals novel candidates for immune checkpoint inhibition Campbell B, Angelini P, Light N, Bouffet E, Larouche V, Samuel D, Stearns D, Cole K, Opocher E, Sabel M, George B, Ziegler D, Laperriere N, Meyn S, Malkin D, Shlien A, Tabori U

9:05-9:20am Integration of multi-region (epi)genomics PATH-45 with multimodality advanced imaging highlights glioma intratumoral heterogeneity Verburg N, Johnson K, Barthel F, Taylor M, Costello J, de Witt Hamer P, Wesseling P, Verhaak R

9:20-9:30am The natural course of hypermutator PATH-37 gliomas Kamiya-Matsuoka C, Shaw K, Loghin M, Penas- Prado M, O’Brien B, Weathers S, Alfaro-Munoz K, Yung W, de Groot J

9:30-9:40am Automated histopathologic classification of PATH-46 brain tumors using artificial intelligence Xie Q, Han D, Faust K, Aldape K, Zadeh G, Volynskaya Z, Djuric U, Diamandis P

9:40-9:45am Characteristic molecular profile changes GENE-10 in primary and recurrent gliomas depending on their histopathology Mukasa A, Nomura M, Saito K, Aihara K, Nagae G, Nejo T, Tanaka S, Takayanagi S, Takahashi S, Omata M, Nakamura T, Narita Y, Muragaki Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Saito N

9:45-9:50am H3F3A and TERT promoter mutations are PATH-34 poor prognosticators in pediatric low-grade gliomas Li K, Yang R, Chan A, Chung N, Shi Z, Wu J, Ng H

9:50-9:55am Comprehensive genomic profiling comparing PATH-20 primary CNS lymphoma to systemic diffuse large B cell lymphoma reveals biomarkers indicating potential benefit from immune checkpoint inhibitors Severson E, Vergilio J, Gay L, Daniel S, Elvin J, Suh J, Covert M, Brown C, Miller V, Stephens P, Ross J, Ramkissoon S

9:55-10:00am Molecular subgroups of adult ependymal PATH-24 tumors: an analysis of the German Glioma Network Witt H, Gramatzki D, Hentschel B, Pajtler K, Schackert G, Capper D, Sahm F, von Deimling A, Westphal M, Herrlinger U, Pietsch T, Löffler M, Reifenberger G, Pfister S, Tonn J, Weller M

10:00-10:05am Deep convolutional neural networks provide NIMG-35 rapid diagnosis of fresh brain tumor specimens imaged with Stimulated Raman Histology Hollon T, Pandian B, Niknafs Y, Lewis S, Camelo- Piragua S, Orringer D



CONCURRENT SESSION 7CImmunology - Preclinical and Clinical IModerators: Duane Mitchell, Hideho OkadaYerba Buena Salon 7

8:30-8:35am Introduction David Reardon

8:35-8:50am Therapeutic potential of chlorotoxin-IMMU-08 redirected CAR-T cells against heterogeneous glioblastomas Wang D, Wright S, Chang W, Starr R, Yang X, Aguilar B, Brito A, Sarkissian A, Badie B, Forman S, Barish M, Brown C

8:50-9:00am H3.3K27M mutation-derived novelIMMU-41 neoantigen – characterization of the HLA-A2- binding epitope and a specific T cell receptor for development of T cell-based immunotherapy Chheda Z, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Carrera D, Shrivastav S, Liu S, Downey K, Chuntova P, Watchmaker P, Mueller S, Pollack I, Rajalingam R, Montero Carcaboso A, Mann M, Sette A, Hou Y, Okada H

9:00-9:10am Glioblastoma-derived IL-6 induces IMMU-38 immunosuppressive peripheral myeloid cell PD-L1 expression and tumor progression Lamano J, Lamano J, Choy W, Veliceasa D, DiDomenico J, Oyon D, Quaggin-Smith J, Fakurnejad S, Ampie L, Li D, Kesavabhotla K, Kaur R, James C, Parsa A, Bloch O


PEDIATRIC BASIC SCIENCE RESEARCH AWARD

PEDIATRIC BASIC SCIENCE RESEARCH AWARD


9:10-9:15am Lin-CCR2+ hematopoietic stem cells IMMU-65 overcome resistance to PD-1 blockade Flores C, Wildes T, Drake J, Abraham R, Mitchell D

9:15-9:20am Controlled expression of IL-12 improves IMMU-34 survival in glioma by activating the immune response in mice and humans Barrett J, Cai H, Miao J, Khare P, Chan T, Cooper L, Lebel F

9:20-9:25am ONO-AE3-208 promotes anti-tumor immune IMMU-42 activity and survival in glioma models Kohanbash G, Kotani T, Chuntova P, Shoger K, Jahan N, Shrivastav S, Carrera D, Downey K, Castro B, Takeda K, Okada H

9:25-9:30am Strategy to enhance DC migration for IMMU-57 increased efficacy of dendritic cell vaccine immunotherapy Dastmalchi F, Karachi A, Azari H, Mitchell D, Rahman M

9:30-9:35am Remodeling immunity against IMMU-29 medulloblastoma via RNA loaded nanoparticles Sayour E, De Leon G, Grippin A, Flores C, Pham C, Mitchell D

9:35-9:40am A phase 1 study of PF-06840003, an oral ATIM-29 indole 2,3-dioxygenase 1 (IDO1) inhibitor in patients with malignant gliomas Reardon D, Desjardins A, Rixe O, Cloughesy T, Alekar S, Gamelin E, Williams J, Meissen J, Taylor C, Lassman A

9:40-9:45am Expression of PD-L2, in glioblastoma; IMMU-10 implications as a biomarker for immunotherapy Ricklefs F, Hayes J, Speranza M, Krenzlin H, Costello J, Freeman G, Westphal M, Lamszus K, Chiocca E, Lawler S

9:45-9:50am Optical barcoding reveals immunoediting IMMU-62 of the clonal architecture and modulation of gene expression signatures in a syngeneic glioma model Mohme M, Maire C, Riecken K, Alawi M, Dührsen L, Neumann K, Lange T, Failla A, Zapf S, Fehse B, Westphal M, Lamszus K

9:50-9:55am Temozolomide-resistant CAR-T enhances IMMU-01 glioblastoma clearance by concurrent chemotherapy and immunotherapy Sampath P, Sengupta S, Junghans R

9:55-10:00am Checkpoint molecule B7-H3 is highly IMMU-45 expressed on medulloblastoma and proves to be a promising candidate for CAR T cell immunotherapy Theruvath J, Heitzeneder S, Majzner R, Cui K, Nellan A, Graef C, Cheshier S, Mackall C, Mitra S

10:00-10:05am Controlled local expression of IL-12 as gene IMMU-33 therapy concomitant with systemic chemotherapy improves survival in glioma Barrett J, Cai H, Miao J, Khare P, Dalsing- Hernandez J, Gonzales P, Chan T, Cooper L, Lebel F


10:10-10:20am BREAK Yerba Buena Foyer CONCURRENT SESSION 8APediatrics - Basic ScienceModerators: Michael Taylor, Robert Wechsler-ReyaYerba Buena Salon 9

10:20-10:30am Yap1 is necessary for tumorigenesis PDTM-11 and cancer stem cellmaintenance in SHH- induced medulloblastomas Natarajan S, George J, Olson J, Camargo F, Yun K

10:30-10:40am Targeting an olig2-dependent pathway TMOD-30 to inhibit tumor growth in primary and recurrent medulloblastoma He X, Zhang L, Lu R

10:40-10:50am Context-specific tumor suppressive function STEM-21 of the canonical Wnt pathway in pediatric medulloblastoma highlights a therapeutic strategy for treatment-refractory subgroups Manoranjan B, Venugopal C, Kameda-Smith M, Bakhshinyan D, Subapanditha M, Doble B, Singh S

10:50-10:55am Characterization of the senescence-PDTM-47 associated secretory phenotype in pilocytic astrocytoma and its role in oncogene- induced senescence Buhl J, Selt F, Hielscher T, Sahm F, Capper D, Usta D, Ecker J, Oehme I, van Tilburg CM, von Deimling A, Schuhmann MU, Korshunov A, Jones D, Brummer T, Pfister SM, Witt O, Milde T

10:55-11:00am Genetic susceptibility and evolution of PDTM-25 pediatric IDH-mutant infiltrating astrocytomas Bornhorst M, Goecks J, Boue D, Broniscer A, Hwang E, Koschmann C, Marks A, Mody R, Mueller S, Orr B, Packer R, Solomon D, Turner J, Vortmeyer A, Nazarian J, Ho C

11:00-11:10am Investigating pediatric GBM using in vivo PDTM-45 somatic mouse mosaics with locus-specific, stably-integrated transgenic elements Kim G, Dutra-Clarke M, Levy R, Park H, Sabet S, Molina J, Akhtar A, Bannykh S, Danielpour M, Breunig J

11:10-11:20am Pediatric low-grade gliomas with CRAF gene PDTM-40 fusions are therapeutically distinct from BRAF-fusions based on dimerization mediated by N-terminal fusion partner Jain P, Fierst T, Han H, Smith T, Storm P, Waanders A, Resnick A




11:20-11:30am TCR Vb clonal expansion predicts response IMMU-30 to adoptive immunotherapy against medulloblastoma Flores C, Wildes T, Pham C, Abraham R, Mooree G, Mitchell D

11:30-11:40am Analysis of paired BRAFV600E mutant PDTM-38 glioma patient samples identifies novel resistance mechanisms to targeted BRAF inhibition Mulcahy Levy J, Sanford B, Morin A, Green A, Flannery P, Jones K, Banerjee A, Solomon D, Nicolaides T

11:40-11:45am Targeted inhibition of EZH2 and BET PDTM-28 bromodomain proteins for the treatment of diffuse intrinsic pontine gliomas Piunti A, Morgan M, Bartom E, Louis N, He X, Zhang A, Horbinski C, Marshall S, Rendleman E, Takahashi Y, Misharin A, Abshiru N, Lulla R, Saratsis A, Kelleher N, James C, Shilatifard A, Hashizume R

11:45-11:50am Rare SOX9+ cells behind MYC-driven TMOD-31 medulloblastoma recurrence Bolin S, Savov V, Borgenvik A, Garancher A, Rosén G, Suryo Rahmanto A, Hutter S, Rusert J, Fotaki G, Hill R, Dubuc A, Remke M, Cancer M, Ramaswamy V, Clifford S, Sangfelt O, Schüller U, Taylor M, Wechsler-Reya R, Weishaupt H, Swartling F

11:50-11:55am CD271 (p75NTR) as a novel diagnostic PDTM-05 marker and therapeutic target for SHH medulloblastoma Liang L, Morrison L, Tatari N, Ramaswamy V, Del Bigio M, Taylor M, Hawkins C, Chan J, Werbowetski-Ogilvie T


CONCURRENT SESSION 8BStem CellsModerators: Anita Hjelmeland, Sheila SinghYerba Buena Salon 8

10:20-10:30am Super-enhancer screen identifies lipid STEM-10 metabolism as a cancer stem cell dependency in glioblastoma Gimple R, Mack S, Rich J

10:30-10:40am Genes preserving stem cell state in Group 3 TMOD-03 MB BTICs contribute to therapy evasion and relapse Bakhshinyan D, Adile A, Venugopal C, Singh M, Qazi M, Manoranjan B, Kameda-Smith M, Singh S

10:40-10:50am Targeting the SCF Ubiquitin Ligase in STEM-16 Glioblastoma Pinkham K, Hashemiaghdam A, Badr C

10:50-11:00am Quaking (Qki) loss enhances GSC stemness STEM-25 and promotes gliomagenesis through regulating intracellular vesicle trafficking Shingu T, Hu J

11:00-11:10am CRISPR/Cas9-edited human neural stem cells TMOD-42 give rise to brain tumors resembling glioblastomas Koga T, Benitez J, Markmiller S, D’Antonio M, Parisian A, Saberi S, Turner K, Hessenauer M, Thorne A, Zanca C, Mischel P, Frazer K, Yeo G, Cavenee W, Furnari F

11:10-11:20am Genetic editing of neural stem cells for STEM-37 intranasal therapeutic delivery to malignant brain tumors Yu D, Kim J, Kanojia D, Han Y, Mathis J, Chen C, Aboody K, Lesniak M, Balyasnikova I

11:20-11:25am Identification of novel targets in STEM-13 glioblastoma stem cells through CRISPR-Cas9 screening Xie Q, Prager B, Rich J

11:25-11:30am The conserved tumor suppressor Lgl1 STEM-05 regulates adult oligodendrocyte progenitor cell division mode and prevents premalignant phenotypes Daynac M, Petritsch C

11:30-11:35am Sox2 activates the expression of onco-miR-STEM-38 486-5p Lopez-Bertoni H, Michelson N, Kotchetkov I, Li Y, Laterra J

11:35-11:40am A translational repression program is STEM-36 associated with the stem cell state in glioblastoma Lee C, Yeu Y, Guenther U, Hwang T, Jankowsky E, Rich J

11:40-11:45am Targeting glioblastoma stem cells by STEM-31 perturbing a novel gene regulatory cluster to reduce tumor recurrence Deng C, Sebastian M, Le S, Chen D, Thomas N, Tran D

11:45-11:50am Transcriptome analysis of glioma stem-like STEM-39 cells reveals SOX2 regulates miR-425-5p expression Acanda de la Rocha A, Lopez-Bertoni H, Martínez- Vélez N, Guruceaga E, González-Huarriz M, Laterra J, Alonso Roldán M

11:50-11:55am The role of symmetric cell division in post STEM-40 therapy glioma stem cell expansion Baisiwala S, Hall R, Park C, Ahmed A




CONCURRENT SESSION 8CImmunology - Preclinical and Clinical IIModerators: Peter Fecci, Gary KohanbashYerba Buena Salon 7

10:20-10:35am Allogeneic tumor lysate / autologous ATIM-13 dendritic cell vaccines in newly diagnosed glioblastoma: Results of clinical trial MC1272 Parney I, Gustafson M, Peterson T, Steinmetz S, Dietz A

10:35-10:45am Alliance A071101: A phase II randomized ATIM-14 trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma Bloch O, Shi Q, Anderson S, Knopp M, Raizer J, Clarke J, Waziri A, Colman H, Bruce J, Olson J, Schwerkoske J, Parsa A, Uhm J, Kumthekar P, Galanis E, Parney I

10:45-10:55am Phase 2 trial of SL-701, a novel immunotherapyATIM-10 comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and survivin, in adults with second-line recurrent GBM Reardon D, Nabors B, Kumthekar P, Badruddoja M, Fink K, Lieberman F, Hu J, Dunbar E, Walbert T, Schiff D, Sherman J, Tran D, Ashby L, Butowski N, Iwamoto F, Moertel C, Schulder M, Chen J, Bullington J, Shemesh S, Brooks C, Goswami T, Peereboom D

10:55-11:05am PD-L1 expression predicts survival in IMMU-13 newly diagnosed glioblastoma patients receiving vaccine immunotherapy but not standard therapy alone DiDomenico J, Veliceasa D, Choy W, Oyon D, Lamano J, Ampie L, Parsa A, Bloch O

11:05-11:10am Phase 2 study to evaluate the clinical efficacy ATIM-12 and safety of MEDI4736 (durvalumab [DUR]) in patients with bevacizumab (BEV)- refractory recurrent glioblastoma (GBM) Reardon D, Kaley T, Dietrich J, Clarke J, Dunn G, Lim M, Cloughesy T, Gan H, Park A, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Venhaus R

11:10-11:15am Immunomarkers in the DNX-2401 (Delta-24-ATIM-08 RGD) oncolytic virus phase I clinical trial Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez- Canales J, Wistuba I, Hess K, Alonso M, Tejada S, Diez Valle R, Ewald B, Tufaro F, Lang F

11:15-11:20am Adoptive immunotherapy using lymphokine-ATIM-22 activated αβ T-cells improves temozolomide- induced lymphopenia in patients with glioma Kanemura Y, Sumida M, Okita Y, Yoshioka E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Nozaki Y, Takada A, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M

11:20-11:25am Population pharmacokinetic (PPK) analysis ATIM-19 of nivolumab flat and weight-based dosing regimens and associations with safety in patients with recurrent glioblastoma (rGBM) treated in checkMate 143 Shen J, Hruska M, Zwirtes R, Potter V, Paliwal P, Roy A, Bello A, Suryawanshi S, Lim M

11:25-11:35am Characterizing the immune landscape of IMMU-20 PD-1/PD-L1 in brain tumor immune cell population using CyTOF mass cytometry Lee A, Davidson, MD T, Galvez M, Nathanson D, Wang A, Liau L, Prins R

11:35-11:45am Enhanced T cells tumor recognition using IMMU-25 dendritic cells pulsed with chimeric RNAs encoding full-length LAMP-1 fusion constructs Yang C, Dechkovskaia A, Drake J, Guimaraes F, Kubilis P, Huang J, Mitchell D

11:45-11:55am Selection of glioma T-cell therapy targets IMMU-52 based on the analysis of tumor immunopeptidome and expression profiles Carrera D, Hayes J, Mueller S, Shelton S, Weinschenk T, Song C, Fritsche J, Schoor O, Kuttruff- Coqui S, Hilf N, Kohanbash G, Watchmaker P, Oldham M, Costello J, Singh H, Okada H



12:00-12:30pm Highlights of SNO 2017 Yerba Buena Salon 7 Manish Aghi, Frank Furnari, Vinay Puduvalli

12:30pm ADJOURN

Save the date!23 R D A N N UA L M E E T I N G and E D U C AT I O N D AY

O F T H E S O C I E T Y F O R N E U R O - O N C O L O G YNovember 15-18, 2018

New Orleans, Louisiana

N O T E S


N O T E S


N O T E S

Society for Neuro-OncologyPO Box 273296 Houston, TX 77277-3296Tel: 713-526-6900 E-Fax: 801-421-0269

www.soc-neuro-onc.org


The Society for Neuro-Oncology gratefully acknowledges the SNO Platinum Partners listed below. Their on-going support allows SNO to fulfill its mission to advance neuro-oncology research and education.

The Society for Neuro-Oncology wishes to express appreciation to the organizations listed below for their promotional support of this meeting.

Benefactor Level

Contributor Level

Personalized Immune Therapies

DC VAX®

T E C H N O L O G Y

NASDAQ: NWBO | NWbio.com | [email protected]

The conference organizing committee wishes to express appreciation to the following company for its commitment to continuing medical education by providing an educational grant in support of this conference.

Documents

November 16-19, 2017 Marriott Marquis San Francisco ... SNO_Program_fin… · Marriott Marquis San Francisco, California. ... Kohichi Ichimura Kurt Jaeckle Rakesh Jalali ... Paul